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FUNCTIONAL CHARACTERIZATION OF SCN5A, THE CARDIAC SODIUM
CHANNEL GENE ASSOCIATED WITH CARDIAC ARRHYTHMIAS
AND SUDDEN DEATH

LING WU

ABSTRACT

The cardiac sodium channel α subunit Nav1.5 (encoded by the SCN5A gene)
plays an important role in the generation and propagation of electrical signals in the heart,
and can cause cardiac arrhythmias, heart failure and sudden death when mutated or
dysregulated. However, the precise composition of the multi-protein complex for the
sodium channel has not been completely defined. The molecular mechanisms by which
Nav1.5 mutations cause cardiac arrhythmias have not yet been well-studied in vivo. It
remains to be explored whether Nav1.5 is expressed in other tissues and plays novel roles
in other tissues or organs. This dissertation addresses these aspects of Nav1.5 regulation.
I found that MOG1, a small protein that is highly conserved from yeast to humans,
is a central component of the channel complex and distinctly modulates the physiological
function of Nav1.5. A yeast two-hybrid screen identified MOG1 as a new protein that
interacts with the cytoplasmic loop II (between transmembrane domain DII and III) of
Nav1.5. The interaction was further demonstrated by both in vitro GST pull-down and in
vivo co-immunoprecipitation assays. Co-expression of MOG1 with Nav1.5 in HEK293
cells increased sodium current densities, whereas two siRNAs that knocked down
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expression of MOG1 decreased current densities. In neonatal myocytes, over-expression
of MOG1 increased current densities nearly two-fold, and MOG1 siRNAs downregulated the sodium currents. Immunostaining revealed that in the heart, MOG1 was
expressed in both atrial and ventricular tissues and was highly localized in the
intercalated discs. These results suggest that MOG1 may be a critical regulator of
sodium channel function in the heart and reveal a new function for MOG1. Furthermore,
I showed that MOG1 increased sodium current density by increasing cell membrane
localization of Nav1.5.

This study further demonstrates the functional diversity of

Nav1.5-binding proteins, which may be important for the function of Nav1.5 under
different cellular conditions.
The second major project I worked on was identification by microarray analysis
of genes differentially expressed in transgenic mice with cardiac expression of LQTS
mutation N1325S of SCN5A. I identified 33 genes in five different functional groups
that showed differential expression.

STAT1, which encodes a transcription factor

involved in apoptosis and interferon response, showed the most significant difference of
expression between TG-NS and control mice (a nearly 10-fold increase in expression, P =
4 x 10-6). The results were further confirmed by quantitative real-time PCR and Western
blot analyses. Accordingly, many interferon response genes also showed differential
expression in TG-NS hearts. This study represents the first microarray analysis for LQTS
and implicates STAT1 in the pathogenesis and progression of LQTS and heart failure
developed in the transgenic mice.
The third project focused on the distribution of Nav1.5 protein in the mouse brain
which was investigated using immunohistochemistry. Immuno-staining with a Nav1.5-
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specific antibody revealed that Nav1.5 protein was localized in certain distinct regions of
brain including the cerebral cortex, thalamus, hypothalamus, basal ganglia, cerebellum
and brainstem. Notably, I found that Nav1.5 protein co-localized with neurofilaments
and clustered at a high density in the neuronal processes, mainly axons. These results
suggest that Nav1.5 protein may play a role in the physiology of the central nervous
system (generation and propagation of electrical signals by axons).
These studies on Nav1.5 provide new insights into the regulation of the function
of Nav1.5, and shed light on the possible pathogenetic mechanism of cardiac arrhythmias
at the molecular level.
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CHAPTER I

GENERAL INTRODUCTION

1.1. Sodium channel Nav1.5 and its functions
1.1.1. Sodium channel gene family
Voltage-gated sodium channels are transmembrane proteins that are critical to the
generation and rapid propagation of the electrical signals (action potentials) in excitable
membranes of cardiomyocytes, neurons, and other cells. To date at least twelve different
sodium channel α-subunit genes have been cloned and they include SCN1A (brain,
chromosome 2q23-q24), SCN2A (brain, 2q22-q23), SCN3A (brain and dorsal root
ganglion or DRG, 2q24-q31), SCN4A (skeletal muscle, 17q23.1-q25.3), SCN5A (heart,
3p21), SCN6A (uterus and heart, 2q21-q23), SCN7A (glial cells, DRG, 2q21-23), SCN8A
(brain, DRG and spinal cord, 12q13), SCN9A (DRG, brain and spinal cord, 2q24),
SCN10A (DRG, 3p22-24), SCN11A (DRG, 3p21-24), and SCN12A (central nervous
system, DRG, non-neural tissues, 3p23-p21.3) (George et al. 1992; Jeong et al. 2000;
Novakovic et al. 2001; Ogata et al. 2000; Wang et al. 1996). The sodium channels are
1

related to the founder member, the voltage-gated sodium channel from the electric eel
electroplax, and also related to each other by sequence homology and a conserved
structure consisting of four transmembrane domains, each of which is composed of six
transmembrane segments (Balser et al. 1999; Catterall et al. 2000; Wang et al. 1996;
Wang et al. 1995a). Dysfunction of sodium channels causes multiple human diseases.
Mutations in the cardiac sodium channel gene SCN5A cause cardiac arrhythmias and
sudden death associated with long QT syndrome (LQTS), idiopathic ventricular
fibrillation and Brugada syndrome, and cardiac conduction disease (Chen et al. 1998;
Dumaine et al. 1996; Schott et al. 1999; Tan et al. 2001; Wan et al 2001; Wang et al.
2000; Wang et al . 2001; Wang et al. 1995a). Mutations in the skeletal muscle sodium
channel gene SCN4A cause hyperkalemic periodic paralysis and paramyotonia congenital
(Ptacek et al. 1992; Ptacek et al. 1991). Mutations in the brain sodium channel gene
SCN1A, SCN2A and SCN3A cause generalized epilepsy with febrile seizures type 2
(Escayg et al. 2000).
Based on the channel sensitivity to blockade by TTX on the connecting segment
between S5 and S6, the tetrodotoxin (TTX) binding site, sodium channels are classified
into three types: TTX-sensitive sodium channels (TTXs; TTX, IC50=1-5 nM), TTXresistant Na channels (TTXr; 0.2-1 µM TTX), and TTX-insensitive Na channels (TTXi;
30-100 µM TTX) (Donahue et al. 2000, Fozzard et al. 1996). The Nav1.5 channel
encoded by SCN5A gene is TTX-resistant (Gellens et al. 1992). TTXr Na channels
generate currents that are slower, but recover from inactivation much faster than those
from TTXs channels (Elliott et al. 1993), suggesting a possible role of TTXr sodium
channels in sustained firing of neurons or as pace-makers.
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1.1.2. Cardiac sodium channel Nav1.5
The human cardiac sodium channel Nav1.5 belongs to the voltage-gated sodium
channel family, and is encoded by the SCN5A gene. This gene is located on chromosome
3p21 and contains 27 introns and 28 exons (Gellens et al. 1992). The human SCN5A
gene has two alternatively spliced variants, Nav1.5c and Nav1.5d. Nav1.5c contains 2,015
amino acids without glutamine at position 1077 compared to wild type Nav1.5 with 2,016
amino acids, while Nav1.5d has a 40 amino acid deletion in the intracellular loop II
between domain II and domain III (Gellens et al. 1992, Makielski JC et al. 2003,
Camacho et al. 2006). The cardiac sodium channel Nav1.5 was initially cloned from the
human cardiac cDNA library. Nav1.5 is mainly expressed in the heart, although it is also
expressed in brain, DRG and skeletal muscle at a much lower level (Gellens et al. 1992,
Hartmann et al. 1999, Plummer et al. 1999). Nav1.5 is highly homologous to Nav1.8
(82%) and Nav1.9 (72%), which are mainly expressed in the peripheral nervous system
(Plummer et al. 1999, Kerr et al. 2004) on the amino acid level.
Nav1.5 is the pore-forming α subunit of the cardiac sodium channel. It consists of
four homologous domains (I-IV) with each domain composed of six transmembrane αhelices (Fig. 1.1). There are at least four different β-subunits, β1, β2 β3 and β4, that are
associated with the α subunit. The β1 subunit has been detected in skeletal muscle, heart
and brain tissues (Makita et al. 1994), whereas the β3 subunit has been identified in the
brain, kidney, skeletal muscle and heart (Morgan et al. 2000, Stevens et al. 2001). The β2
and β4 subunits are also expressed in the heart, but at significantly lower levels than those
in the brain (Maier et al. 2004; Eubanks et al. 1997, Malhotra et al., 2001, Yu et al., 2003).
The structure of β1 is most similar to that of the β3 subunit with a noncovalent link to the
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α subunit (Isom et al., 1992, Morgan et al., 2000, Qu et al., 2001). The β2 and β4
subunits are more similar to each other with an unpaired cysteine that interacts with the α
subunit by a disulfide bond (Hartshorne et al., 1984, Yu et al., 2003). The β1 and β2
subunits are similar to cell adhesion molecules in their extracellular immunoglobulin-like
motifs (Isom et al.1996), which is consistent with their function for regulating the
targeting and localization of the sodium channel to the cell membrane (Novakovic et al.
2001).

1.1.3. Functional characterization of cardiac sodium channel Nav1.5
The major functions of Nav1.5 are to generate the cardiac action potential and to
maintain rapid conduction of electrical signals through cardiac tissues. This voltage–
gated sodium channel exists in three main transitional states: closed, open (activated) and
inactivated. These channel states control sodium ion permeability through the channel
into the cardiac cell. Sodium channel acticvation allows sodium ion influx into the cell
and inactivation blocks entry of inward sodium ions. Inactivation is mediated by the
inactivation gate, a cytoplasmic link between domain III and domain IV where the triad
IFM (Ile 1488, Phe 1489, Met 1490) serves as a hydrophobic ‘latch’ that limits or
restricts sodium ion pass through the pore (West et al. 1992). When the cell membrane
senses a voltage change (i.e., depolarization), the voltage sensor (the S4 segment) moves
outward (towards external face).

Following this change, the four transmembrane

domains (I-IV) undergo several conformational changes whereby the overall channel
conformation is in the open state. The sodium ions enter the cells rapidly, which initiates
the

cardiac

action

potential.

Several

4

milliseconds

later,

the

inactivation

Fig. 1.1. The structure of Nav1.5. Sodium channel Nav1.5 consists of four
transmembrane domains (I-IV) and five cytoplasmic domains. Each transmembrane
domain contains six alpha-helix segments (S1-S6). Cytoplasmic domains are composed
of the N-terminus, loops I, II, III and C-terminus.
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gate closes and blocks movement of sodium ions across the cell membrane. The sodium
channel is then converted to the inactivated state. The recovery of the sodium channel to
reopen is voltage-dependent. Highly polarized (-80 to 90 mV) cell membrane can be
depolarized rapidly by stimuli due to more sodium channels reopening. While partially
depolarized cells with potentials close to threshold -70 mV causes a much slower
upstroke because of the inactivation of some channels. The recovery of channels from
inactivation is also time-dependent. Sodium channels typically activate within 200-300
µs and inactivate completely within 2-5 ms.

1.1.3. 1. Nav1.5 and the cardiac action potential
The cardiac action potential refers to changes in voltage that travel along the
membrane of the cardiac cell. These changes are composed of 5 phases (0-4) which
collectively make up the cardiac action potential.

The sodium channel makes a

contribution in two phases of the action potential, the upstroke of rapid depolarization or
phase 0 and the plateau phase or phase 2 (Fig. 1.2). Phase 3 is the repolarization phase.
Phase 4 is the resting phase with a membrane potential of approx -90 mV in ventricular
myocardium, which is sustained until the cell is stimulated by an external stimulus.
During phase 4, most sodium channels are in the closed state, the activation gate is in the
closed state and the inactivation gate is in an open state. Upon the external stimulus, the
membrane potential of the cell achieves a threshold voltage (about -70 mV) and initiates
the rapid depolarization phase (Phase 0) by the activation of the sodium channels. When
the cell is depolarized, the channel is changed from a closed state to the open state. In
this open conformation, both the activation and inactivation gates are shifted to their open

6

Fig. 1.2. A schematic view of an idealized action potential for ventricular myocytes.
The action potential has 5 phases (numbered 0-4). Phase 4 is the resting membrane
potential, in which the cell is not stimulated, mainly maintained by the movement of K+.
Phase 0 is the rapid depolarization phase due to the rapid influx of Na+. Phase 1 occurs
with the inactivation of the fast Na+ channels and efflux of K+. Phase 2 is the "plateau"
phase sustained by a balance between inward movement of Ca2+ and outward movement
of K+. Phase 3 is the repolarization phase due to the outward IK caused by the opening of
the slow delayed rectifier (IKs) K+ channels, and the rapid delayed rectifier K+ channels
(IKr).
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state. Sodium ions permeate across the channel pore. This is quickly followed by
inactivation of the channels (Phase 1) and the opening of the transient outward K+
channel.

Delayed sodium channel inactivation can cause late sodium currents and

prolong action potential duration (APD). Phase 2 of the action potential represents the
"plateau" phase maintained by the influx of Ca2+ ions through L-type calcium channels,
the influx of sodium ions through sodium channel and Na/Ca exchanger and the efflux of
K+ ions through the slow delayed rectifier potassium channels, IKs. During Phase 3, the
slow delayed rectifier (IKs) and rapid delayed rectifier (IKr) K+ channels remain open and
the L-type Ca2+ channels are inactivated. After membrane repolarization, the sodium
channels convert back to their resting or closed state.
The cardiac electrical impulse originates from the sinoatrial node pacemaker cells
that depolarize spontaneously. The impulse is conducted to and through the atria to the
atrioventricular junction, and then propagates to ventricles via the right/left bundle
branches and Purkinje fibers. Voltage-gated sodium channels, mainly Nav1.5, play a key
role for impulse propagation and conduction.
Sodium ionic currents can be measured under voltage clamp at the whole cell
membrane level, referred to as whole cell patch clamp, a broadly used method to measure
membrane currents from isolated cells. A typical laboratory setup is shown in Fig. 1.3.

1.1.3.2. Nav1.5 and the excitation-contraction coupling (ECC) process
After the cell depolarizes, L-type voltage-dependent calcium channels on the cell surface
open and allow calcium ions to enter the cell. This small amount of calcium entry
stimulates calcium-release channels named ryanodine receptors (RYR2) and triggers a

8

Current

_
Amplifier

Voltage
electrode

+

Output
Signal (V)

Glass
pipette

Bath
solution

Reference electrode

cell

Fig. 1.3 Schematic diagram for a typical electrophysiological laboratory set-up.
The set-up represents a technique for studying ionic currents at the cellular level. A glass
pipette is pressed gently on the cell membrane to form a seal. When suction is applied to
the pipette the membrane breaks and the cytoplasm and pipette solution start to
equilibrate. Cells are voltage-clamped and currents are recorded with the help of
hardware (computer and amplifier) and software (pClamp9.0).
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subsequent release of a larger amount of calcium ions stored in the sarcoplasmic
reticulum (SR). The free calcium ions bind to troponin-C (TN-C), one of the triple
regulatory complexes attached to the thin filaments, inducing a conformational change
and relieving inhibition on the actin-myosin crossbridge by troponin I. These changes
result in a movement between the myosin heads and the actin and cause muscle
contraction.

This physiological process that converts an electrical stimulus to a

mechanical response has been named excitation-contraction coupling (Sandow, 1952).
Recent work has shown that late sodium currents generated by the mutant sodium
channel N1325S of Nav1.5 may lead to intracellular calcium overload (Yong et al. 2007).
Irregularities in Ca2+ transients caused by the altered sodium currents may affect cardiac
cell contractility.

1.2. Cardiac diseases associated with the SCN5A gene
Mutations in the cardiac sodium channel gene SCN5A have been linked to the
pathogenesis of several serious cardiac diseases. Appendix A summarizes the Nav1.5
mutations associated with cardiac diseases. The relationship between Nav1.5 mutations
and the physiological functions associated with the corresponding cardiac diseases is
described as follows.

1.2.1. The Long QT Syndrome (LQTS)
The long QT syndrome (LQTS) is characterized by prolongation of the QT
interval and T wave abnormalities on electrocardiograms (ECG) and it is associated
symptoms including syncope and sudden death caused by a specific ventricular
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arrhythmia, torsade de pointes (Schwartz et al. 1975; Wang et al. 1997). Two major
clinical forms of LQTS have been described based on genetic transmission patterns:
autosomal dominant LQTS (Romano-Ward syndrome) with normal hearing (Ward et al.
1964; Romano et al. 1965) and the much rarer autosomal recessive LQTS (Jervell-LangeNielsen syndrome) that is associated with congenital neural deafness (Jervell et al. 1957).
LQTS can also be sporadic and acquired (Towbin et al. 2001). Although most clinical
symptoms are “triggered” by strong emotional outpouring, exercise and sudden
awakening from sleep, syncope and sudden death can also occur during sleep or at rest
(Keating et al. 2001).

1.2.1.1. Genetics of long QT syndrome (LQTS)
During the past decade, nine LQT genes have been discovered. KCNQ1 (LQT1,
mapped to chromosome 11p15.5) (Wang et al. 1996, Keating et al. 1991), KCNH2 (LQT2,
on chromosome 7q35-36) (Curran et al. 1995, Jiang, 1994), KCNE1 or MinK (LQT5, on
chromosome 21q22) (Splawski et al. 1997, Schulze-Bahr et al. 1997), KCNE2 or MiRP1
(LQT6, on chromosome 21q22 ) (Abbott et al. 1999), KCNJ2 (LQT7, on chromosome
17q23) (Tristani-Firouzi et al. 2002, Plaster er al. 2001) all encode potassium channel
subunits.

SCN5A (LQT3, on chromosome 3p21-24) gene has been shown as the

chromosome 3-linked LQT gene (3p24-p21), and encodes the cardiac sodium channel
protein (Wang et al. 1995a, Jiang, 1994). The LQT8 gene is CACNA1C mapped to
chromosome 12p13, which encodes the alpha 1c subunit of voltage-gated cardiac L Type
calcium channel (Splawski et al. 2004, Jacobs et al. 2006). The first non ion channel
gene to be linked to the LQTS (LQT4, on chromosome 4q25-27) is ANK2, a gene
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encoding ankyrin-B, a member of a family of versatile membrane adapters (Mohler et al.
2003, Schott et al. 1995).

Recent research work reported CAV3, a gene encoding

caveolin-3, an ion channel-associated protein, as a novel LQTS gene (LQT9, on
chromosome 3p25) (Vatta et al. 2006). Heterozygous mutations in all these genes cause
autosomal dominant LQTS (Romano-Ward syndrome). Among LQTS patients, 40-45%
have KCNQ1 mutations, 40-45% have KCNH2 mutations, and 5-8% have mutations in
SCN5A. Less than 1% of clinical cases are reported to have rare LQTS forms, which
include LQT4, LQT5, LQT6, LQT7, LQT8, and LQT9 (Zareba W 2006, Vatta et al.
2006). Homozygous mutations in KvLQT1 and KCNE1 result in autosomal recessive
LQT (Jervell-Lange-Nielsen syndrome) (Splawski et al. 1997; Neyroud et al. 1997).

1.2.1.2. SCN5A mutations and LQT3
Long QT syndrome type 3 (LQT3) results from gain-of-function mutations in the
cardiac sodium channel Nav1.5.

A late persistent inward current is a common

electrophysiological property of mutations in Nav1.5 leading to LQTS. This late sodium
current results in a gain of sodium current during the plateau of the action potential, and
thus results in a longer plateau phase of the cardiac action potential and a prolongation of
the Q-T interval. (Bennett et al. 1995, Clancy et al. 1999). To date, there are at least
forty-seven mutations reported to be associated with LQT3 (Appedix A).

These

mutations include thirty-eight missense mutations, six deletion mutations, one splice
mutation and two insertion mutations. Among them, 15 mutations are located in Domain
IV. The most studied of these mutations are Nav1.5-∆KPQ, Nav1.5-N1325S, Nav1.5R1644H, Nav1.5-D1790G and Nav1.5-I1768V.
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Nav1.5-∆KPQ, Nav1.5-N1325S and

Nav1.5-R1644H mutations cause persistent late inward sodium currents and exhibit
prolonged APD, which are due to dispersed reopenings or long-lasting bursts (Dumaine
et al. 1996).

In contrast, both Nav1.5-D1790G and Nav1.5-I1768V do not enhance

sustained inward currents (An et al. 1998, Rivolta et al. 2002). Mutant channels with
Nav1.5-D1790G cause the prolonged APD by increasing [Ca2+]i transient at slow heart
rates (Wehrens et al. 2000), and Nav1.5-I1768V induces prolonged APD by enhancing
recovery from inactivation and changing the steady-state inactivation kinetics (Rivolta et
al. 2002).

1.2.1.3. Mouse models for LQT3
Several SCN5A mutations have been characterized in either transgenic
overexpression or knock-in mice. Three mouse models for LQT3 have been established:
SCN5A-∆KPQ knock-in, SCN5A-1795insD knock-in and SCN5A-N1325S transgenic
overexpression models (Nuyens et al. 2001, Remme et al. 2006, Tian et al. 2004).
Wang et al. identified the ∆KPQ mutation first in two unrelated LQT3 families
(Wang et al. 1995), and later found the same mutation in two other unrelated families
(Wang et al. 1995b). The ∆KPQ mutation is the first SCN5A mutation identified in
humans and is located in the highly conserved portion of the cytoplasmic III-IV linker,
the putative channel inactivation gate. The stability of inactivation of the cardiac sodium
channel during prolonged depolarization was reported to be decreased in mutant channels
with the ∆KPQ mutation, which resulted in prolongation of APD and facilitated the
development of arrhythmogenic early afterdepolarizations (EADs) (Bennett et al. 1995).
This SCN5A-delKPQ mutation was further overexpressed in mice (Nuyens et al. 2001).
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Homozygous embryos (SCN5A∆/∆) died at embryonic day 10.5 when SCN5A becomes
important for cardiac excitability. Mice heterozygous for knock-in ∆KPQ (SCN5A∆/+)
exhibited the typical LQT3 features including prolonged action potential and QT
intervals, low resting heart rate, early afterdepolarization, ventricular arrhythmias and
sudden death (Nuyens et al. 2001). Increased late inward sodium currents during the
plateau phase of action potential were blocked by mexiletine, a sodium channel blocker.
Ventricular tachyarrhythmias and ventricular extrasystoles were the results of prolonged
action potential duration and EAD in SCN5A∆/+ mice (Nuyens et al. 2001).
The second mouse model for a LQTS mutation is the SCN5A 1795insD/+ mouse.
This mutation results from an insertion of an aspartic acid in the C-terminus of SCN5A.
This mutation was identified in a Dutch family with a high incidence of LQT3 and
Brugada syndrome (Bezzina et al.1999). Expression of 1795insD mutation in Xenopus
oocytes and HEK293 cells reduced sodium current amplitude, changed channel kinetics
characterized by a positive shift of the activation curve, a negative shift of the
inactivation curve, disruption of fast inactivation and delayed recovery of sodium channel
from inactivation (Bezzina et al.1999, Marieke et al. 2000). This mutation also enhances
channel bursting, leading to a persistent component of noninactivating current (Clancy et
al. 2002).

Heterozygous mice expressing 1795insD, SCN5A1795insD/+, exhibited

bradycardia, increased PQ interval, prolonged QRS duration and QT interval compared
with wild-type mice on ECG (Remme et al. 2006). Epicardial mapping in Langendorffperfused hearts displayed conduction delay in the right ventricle of SCN5A1795insD/+ mice
(Remme et al. 2006). Whole cell patch clamp revealed reduction in peak sodium current
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density, prolongation of the action potential and a delayed time course of current decay
in SCN5A1795insD/+ cardiomyocytes (Remme et al. 2006).
The Nav1.5 N1325S mutation is another well-studied LQT mutation, which
involves a substitution of an asparagine residue by a serine at position 1325 in the
intracellular region between domains DIII S4 and DIII S5. Expression of this mutation in
Xenopus oocytes and HEK293 cells produced persistent late currents and prolonged APD
which can be inhibited by mexiletine and tetrodotoxin (Dumaine et al.1996; Wang et
al.1997). Tian et al. in our laboratory developed a LQT3 mouse model by transgenic
overexpression of Nav1.5 N1325S mutation in the mouse heart using a murine, cardiac
specific α-myosin heavy chain promoter. The LQT3 phenotypes including prolonged QT
interval, syncope, ventricular tachycardia, ventricular fibrillation, and sudden death were
observed in the transgenic mice. Prolonged APD due to the late persistent sodium
current, EAD and a slow recovery from inactivation of INa were detected in transgenic
ventricular myocytes (Tian et al. 2004).

1.2.2. Brugada syndrome
Brugada syndrome is one of the commonly recognized forms of idiopathic
ventricular fibrillation (IVF). IVF refers to ventricular fibrillation occurring without
underlying structural heart disease, metabolic abnormalities or QT interval prolongation
on ECG (Jalife 2000; Viskin et al. 1990). Two commonly recognized forms of IVF
include: (1) IVF with normal ECG; (2) Brugada syndrome with characteristic ECG
features of right bundle branch block (RBBB) and persistent ST segment elevation (STE)
in leads V1 to V3 (Viskin et al 1998).
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Brugada syndrome has been estimated to be responsible for 18-30% of all sudden
deaths and at least 20% of patient death with a normal heart structure (Antzelevitch et al.
2005).

Brugada syndrome can be caused by SCN5A mutations (Chen et al 1998).

SCN5A mutations associated with Brugada syndrome act by a loss-of-function
mechanism.
The SCN5A mutations in patients with Brugada syndrome result in different
electrophysiological abnormalities compared with those known to cause LQTS or
conduction system disease. Mutations in the coding region of SCN5A in three IVF
families were identified in 1998 and those patients have typical ST segment elevation and
RBBB ECG pattern (Chen et al.1998). Later a novel SCN5A mutation (S1710L) was
identified in IVF patients without STE and RBBB on ECG (Akai et al.2000). Research
revealed more than one hundred SCN5A mutations linked to Brugada syndrome and these
mutations are located throughout the SCN5A gene (Appendix A). Most of them are
exonic mutations including seventy-two missense mutations, four deletions, four
frameshifts and one insertion. There are seven mutations in introns affecting RNA
splicing. The physiological effects of SCN5A mutations for Brugada syndrome are more
complicated than those for LQTS because heterologously expressed sodium channel
mutants displayed a broad variety of functional properties (Akai et al. 2000).

For

example, shifts in the voltage-dependence of activation and inactivation are not always
consistent with loss of function. R1512W and S1710L shift the steady-state inactivation
curve to more hyperpolarizing potentials (Rook et al. 1999, Akai et al. 2000), and
A1924T causes a hyperpolarizing shift of the activation curve (Rook et al. 1999). In
contrast, the first mutation T1620M gave a depolarizing shift of steady-state inactivation
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curve when expressed in Xenopus oocytes (Chen et al.1998, Baroudi et al. 2000), but no
effects on inactivation curve when expressed in mammalian tsA201 cells (Baroudi et al.
2000).

Most missense and splice-donor mutations lead to a faster recovery from

inactivation (Chen et al. 1998, Herbert et al. 2006), while frameshift mutations inactivate
the channel, causing a non-functional channel (Chen et al.1998).

1.2.3. Progressive cardiac conduction defect
Loss-of-function mutations in SCN5A were also identified in patients with
progressive cardiac conduction defects (PCCD), also known as Lev-Lenegre disease
(Probst et al. 1999). The progressive cardiac conduction defect is one of the most
common cardiac conduction disturbances characterized by progressive alteration of
cardiac conduction through the His-Purkinje system with prolonged QRS complexes
(Probst et al. 1999). Patients may suffer from syncope or sudden death due to complete
atria-ventricular block.

This disease affects the conductive tissue associated with

myocardial rearrangement and fibrosis (Royer et al. 2005).

Affected conduction

parameters are P wave, PR and QRS interval duration which increases with age (Probst et
al. 2003 and 2006, Royer et al. 2005). Ten mutations in SCN5A have been identified in
patients with the cardiac conduction defect (Appendix A). These mutations include
seven exonic mutations, one frameshift and two splicing mutations. The first SCN5A
mutation related to PCCD was found in the highly conserved +2 donor splicing site of
SCN5A intron 22 in a French family. The T→C substitution mutation results in abnormal
transcriptional products with the deletion of exon 22, which encodes the voltage-sensitive
S4 segment in domain III and results in a non-functional channel (Schott et al.1999,
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Probst et al. 2003). Surprisingly, three missense and one splicing SCN5A mutations were
reported to cause Brugada syndrome and isolated cardiac conduction defect as well
(Kyndt et al. 2001, Smits et al. 2005, Rossenbacker 2004 and 2005). Recently, it was
found that the severity of symptoms increase with age in PCCD patients with SCN5A
mutation W1421X (LQT3).

An SCN5A polymorphism R1193Q was reported to

complement the clinical manifestations of the cardiac conduction defect caused by
nonsense SCN5A mutation W1421X (Niu et al. 2006). Therefore, the mechanism for
PCCD seems complex.

1.2.4. Sudden infant death syndrome (SIDS)
Sudden infant death syndrome (SIDS) is defined as sudden and unanticipated death
of an infant younger than one year (Plant et al. 2006). The death is unexplained after a
thorough investigation, including a complete autopsy and a review of the clinical history.
SIDS is one of the leading causes of infant mortality during the first year of life in
developed countries (Tester et al. 2005). The pathogenesis of SIDS is multifactorial, and
involves abnormalities in respiratory, cardiac, endocrine and potential neurological
functions (Makielski 2006). Prolongation of the QT interval was first detected in 39% of
the siblings and 11 (26%) of parents of infants with SIDS (Maron et al. 1976). SIDS was
previously considered as a form of LQT3 in infants (Moric et al. 2003). Mutation
screening for all known LQTS genes in SIDS identified a SCN5A mutation A1330P,
which increased channel availability and induced faster recovery from inactivation
(Wedekind et al. 2001). Another mutation screen of seven LQTS genes found that 9.5%
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of SIDS patients carried LQTS gene variants, which included four SCN5A mutations (del
AL 586-587, R680H, T1304M, F1486L) and 5 rare genetic variants (S216L, R1193Q,
V1951L, F2004L, P2006A) (Arnestad et al. 2007). All of these variants showed defects
in the voltage-dependent of inactivation (Wang et al. 2007). Expression of S1103Y in
HEK293 cells under different pH demonstrated that acidosis was involved in SIDS,
which is consistent with clinical observations (Plant et al. 2006). Prenatal findings and
postpartum electrocardiograms strongly suggested that sinus bradycardia was related to
severe prolongation of the QTc in infants with SIDS (Schwartz et al. 2000, Beinder et al.
2000). In addition, recent research work showed that mutations in caveolin-3 are also
linked to SIDS, and cause LQT3-like phenotype with an increased late sodium current
(Cronk, 2007).

1.2.5. Sinus node dysfunction
Sinus node dysfunction (SND) is also called sick sinus syndrome which is
accompanied by symptoms such as dizziness or syncope. This syndrome is caused by a
malfunction of the sinus node. The sinus node cell is characterized by initiation of the
automatic depolarization. Calcium channels (Ica,T, Ica,L) make the major contribution for
the action potential upstroke of nodal cells in the center of nodal tissue. In contrast,
sodium channels play a major role in pacemaking in the periphery of sinus node (Kodama
et al. 1997). Mutations in the cardiac sodium channel gene SCN5A were found to cause
sinus node dysfunction. Mutational screening in ten pediatric patients with sick sinus
syndrome from seven families identified six mutations (T220I, P1298L, G1408R,
delF1617, R1623X, and R1632H). Electrophysiological studies by expression of these
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mutations (T220I, P1298L, delF1617 and R1632H) in tsA201 cells identified a loss of
channel function, including a reduced peak sodium current density, hyperpolarizing shifts
in the voltage dependence of steady-state channel availability, and slow recovery from
inactivation (Benson et al. 2003).

The nonsense mutation (R1623X) produced

nonfunctional channels and missense mutation G1408R was demonstrated to silence the
sodium channel function (Benson et al. 2003; Kyndt et al. 2001). These results suggest
that SCN5A mutations reduce myocardial excitability in patients with sinus node
dysfunction.

1.2.6. Atrial dysfunction
Mutations in SCN5A have been linked to atrial dysfunction, including atrial
standstill and atrial fibrillation.

Atrial standstill is a rare arrhythmogenic condition

characterized by the absence of electrical and mechanical activity in the atria. Genetic
analysis for a patient with Brugada syndrome accompanied by atrial standstill revealed a
missense mutation (R367H) in SCN5A. The mutant sodium channel was nonfunctional
when expressed heterologously in Xenopus oocytes (Takehara et al. 2004). SCN5A
mutation L212P is another mutation associated with a severe clinical phenotype in atrial
standstill (Makita et al. 2005). The heterologously expressed L212P mutant channel in
tsA-201 cells exhibited a hyperpolarization shift of steady-state inactivation and delayed
recovery from inactivation. Coinherited atrial-specific gap junction connexin 40 (Cx40)
SNPs with SCN5A mutation L212P may enhance the severity of symptoms by disrupting
the spatial distribution of Cx40 and thus influence atrial conduction and excitability
(Makita et al. 2005). Therefore, SCN5A mutations contribute to the development of atrial
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standstill by reducing sodium channel availability and slowing cardiac impulse
conduction.
Atrial fibrillation (AF) is another atrial dysfunction associated with SCN5A
mutations.

A common loss-of-function H558R polymorphism in SCN5A, which is

presented in one-third of the population, was reported to be more common in AF patients
than in controls (Chen et al. 2007). In a dog model of chronic atrial fibrillation, the
sodium current density decreased with slowing of recovery kinetics in atrial cells (Yagi et
al. 2002).

SCN5A mutations were also identified in patients with both dilated

cardiomyopathy and atrial fibrillation (Olson et al. 2005).

1.2.7. Heart failure
Heart failure is a condition in which the heart is unable to pump a sufficient
amount of blood to meet the needs of the body, which may result from any abnormality
of cardiac structure or function. In a dog model of heart failure induced by sequential
coronary microembolization, the expression of Nav1.5 protein was reduced about 30%
and sodium current density was decreased significantly (Zicha et al. 2004). Mutations in
SCN5A have been shown to increase the risk for dilated cardiomyopathy and heart
failure with atrial fibrillation (Olson et al. 2005).

1.3. Regulation of Nav1.5
The mechanisms that underlie modulation of sodium channel functions have been
complex and vary according to the sodium channels studied. Research work over last
several years identified a few Nav1.5 regulatory proteins (Fig. 1.4).
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They include

auxiliary β subunits, C-terminal interacting proteins including fibroblast growth factor
homologous factor1B (FHF1B), calmodulin, ubiquitin-protein ligase Nedd4 and
syntrophin/dystrophin complex, cytoplasmic loop

I interacting protein 14-3-3, and

cytoplasmic loop II interacting protein ankyrin G. The Nav1.5 channel can also be
modulated by phosphorylation (Fyn, protein kinase A, protein kinase C, glucocorticoid–
inducible kinases SGK1 and SGK3) and dephosphorylation (protein tyrosin phosphatase
H1). I will discuss these Nav1.5 interacting proteins in detail below.

1.3.1. Regulation by auxiliary β subunits
The regulation of Nav1.5 channels by β subunits has been extensively studied. At
least four different β-subunits, β1, β2, β3, and β4, have been identified in the heart with
different expression levels. Co-expression of SCN1B (encoding β1) with Nav1.5 induced
acceleration in the recovery from inactivation in the heart (Nuss et al. 1995). Coexpression of SCN5A with either SCN3b (β3) or SCN1b (β1) in Xenopus oocytes
increased Nav1.5 expression on plasma membrane by threefold (Fahmi et al., 2001), and
induced acceleration in the recovery from inactivation in heart (Nuss et al. 1995, Baroudi
et al. 2000). However, SCN3b and SCN1b have different effects on the kinetics of
Nav1.5, with β3 causing a significant depolarizing shift in steady-state inactivation,
whereas β1 induced faster recovery from inactivation compared to β3 subunit (Fahmi et
al. 2001). The β2 subunit was shown to cause a hyperpolarizing shift in Nav1.5 gating
(Johnson et al. 2006). Recent study showed that a mutation (L179F) in the β4 subunit
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increased the late sodium currents, the similar effect to the LQT3 mutation, ∆KPQ
(Medeiros-Domingo et al. 2007).

1.3.2. Regulation by protein kinases/phosphatases
The cardiac sodium channel has been reported to be subjected to phosphorylation
and de-phosphorylation by kinases or phosphatases. cAMP-dependent protein kinase A
(PKA) and G protein stimulatory α–subunit (Gsα) modulate Nav1.5 upon β-adrenergic
stimulation. Activation of protein kinase A increased sodium currents derived from
cardiac sodium channels (Schreibmayer et al.1994, Frohnwieser et al.1997).

The

underlying mechanism may be related to an increased number of sodium channels on the
plasma membrane. Preincubation with two cell surface protein recycling interrupters,
chloroquine and monensin, prevented the PKA-mediated increase of sodium currents on
cell membrane (Zhou et al. 2000).

Further studies showed that PKA mediated

modulation of the trafficking of sodium channels by phosphorylation of residues in the
cytoplasmic I-II interdomain loop (Ser526 and Ser529 of Nav1.5) (Murphy et al. 1996,
Zhou et al. 2000). In addition, the presence of putative ER ‘retention’ signals in the I-II
interdomain loop of the human cardiac sodium channel is also necessary for PKA–
mediated enhancement of sodium currents (Zhou et al. 2000 and 2002). Matsuda et al.
reported that the N-terminus of the native Gsα was able to modulate the function of the
cardiac sodium channel directly, i.e., independent of PKA (Matsuda et al. 1992). Lu et al.
further found that the mechanism was an increase of the number of sodium channels
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Fig. 1.4. Schematic representation of Nav1.5 and its associating proteins. Ten
proteins that have been reported to be associated with Nav1.5 are represented
schematically. These proteins include FHF1B, calmodulin, Nedd-4-like and syntrophin
that interact with the C-terminus of Nav1.5, ankyrin interacting with the cytoplasmic loop
II between transmembrane domains II and III, and the 14-3-3 protein interacting with the
loop I of Nav1.5. Four kinases/phosphatases, PKA and PTPH1 that interact with the
cytoplamic loop I and C-terminus respectively. PKC and Fyn interact with loop III. Beta
subunits have not been shown here. This Figure was modified from Abriel et al. Trends
Cardiovasc Med 2005;15:35–40).
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on cell surface (Lu et al. 1999). In contrast, activation of α-adrenergic stimulating protein
kinase C (PKC) resulted in the reduction of sodium currents through phosphorylation of
serine 1503 (Serine 1505 in rat) of the cardiac sodium channel (Qu et al. 1996, Tateyama
et al. 2003). Phosphorylation of this serine residue by PKC was further demonstrated to
suppress the sustained sodium channel current (Isus) caused by disease-linked mutations
(Tateyama et al. 2003).

Another tyrosine kinase Fyn has been shown to induce a

depolarizing shift of steady-state inactivation and to accelerate the recovery from
inactivation of Nav1.5 channels when heterologously coexpressed in HEK293 cells with
Nav1.5 (Ahern et al. 2005).
Coexpression of the protein tyrosine phosphatase H1 (PTPH1) in HEK293 cells
shifted the steady-state inactivation curve towards more hyperpolarized potentials, the
function that is mediated by the interaction with PDZ-domain binding motif of Nav1.5
(Jespersen et al. 2006).

Therefore, the function of the cardiac sodium channel is

regulated by phosphorylation and dephophorylation.

1.3.3. The 14-3-3 protein interacts with the cytoplasmic I-II linker of Nav1.5
The 14-3-3 protein is a highly conserved cytosolic protein expressed broadly in
various organisms and tissues. It plays an important role in cell signaling, cell growth,
division, adhesion, differentiation, apoptosis, and ion-channel regulation. The 14-3-3
protein was recently found to interact with cytoplasmic loop I between DI and DII of
Nav1.5 (Allouis et al. 2006). Coexpression of 14-3-3 and Nav1.5 in COS-7 cells shifted
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the steady-state inactivation curve toward hyperpolarizing potentials and slowed the
recovery from inactivation.

1.3.4.

A protein that interacts with the cytoplasmic II-III linker of Nav1.5:

ankyrinG
Ankyrins are intracellular adaptor proteins that link diverse proteins to plasma
membrane and endoplasmic reticulum. Ankyrin-G and ankyrin B have been shown to
modulate the functions of the pore-forming α-subunit of sodium channel. Lemaillet et al.
demonstrated that ankyrin-G interacts with Nav1.5 and this interaction involved a 9amino acid motif in the cytoplasmic loop II conserved through vertebrate sodium
channels (Lemaillet et al. 2003). Further studies revealed that a Brugada syndrome
mutation in Nav1.5 (E1053K) is located in the binding site for ankyrinG. This mutation
prevented the localization of the cardiac sodium channel to membrane in cardiomyocytes
(Mohler et al. 2004).

1.3.5. Proteins that interact with the C-terminal domain of Nav1.5:

FHF1B,

calmodulin, Nedd4-like and syntrophin/dystrophin
The C-terminal domain of Nav1.5 contains 243 amino acid residues that are
important for interactions with several proteins including fibroblast growth factor
homologous factor 1B (FHF1B), calmodulin (CaM), Nedd4-like ubiquitin-protein ligase,
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and syntrophin/dystrophin ( Liu et al. 2003, Tan et al. 2002, Abriel et al 2000, Ou et al
2003).

1.3.5.1. Fibroblast growth factor homologous factor 1B (FHF1B)
Fibroblast growth factor homologous factor 1B (FHF1B) belongs to a subset of
the fibroblast growth factor (FGF) family, one of the largest families of polypeptide
growth factors. Recent research showed that the C-terminus of both Nav1.5 and Nav1.9
interacted with the N-terminus of FHF1B (Liu et al., 2001, 2003). Coexpression of
FHF1B with Nav1.5 shifted the inactivation curve to hyperpolarized potentials, but the
detailed role of FHF1B in Nav1.5 function and regulation is unknown (Liu et al., 2003).

1.3.5.2. Calmodulin
Calmodulin (CaM) is a calcium binding protein that serves as a Ca2+ sensor
through which increased calcium levels are translated into cellular responses by
conformational changes of calmodulin (Nelson et al., 1998). The interaction of CaM
with the IQ motif at the C-terminus of Nav1.5 (I1908-R1918) is controversial with four
studies reporting positive binding (Deschenes et al., 2002, Kim et al., 2004, Tan et al,
2002, Young et al. 2005) and one report of negative binding (Herzog et al. 2003). Data
presented by Tan et al suggested that CaM increased slow inactivation of Nav1.5
significantly by performing studies in tsA201 cells (Tan et al 2002).
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However,

Deschenes et al. did not detect effects of CaM on Nav1.5 by co-expression of CaM and
Nav1.5 in HEK293 cells (Deschenes et al. 2002). Recent studies showed that CaM
induced a hyperpolarizing shift in the voltage dependence of activation with CaM and
Nav1.5 overexpressed in CHO cells (Young et al. 2005). The explanation for these
discrepancies might be due to the endogenous expression of different β-subunits among
studied cells. On the other hand, Wingo et al. proposed a different Ca2+ model for
functional modulation of Nav1.5 by which Ca2+ regulates the function of Nav1.5 by direct
binding to the EF-hand motif in the C-terminal domain of Nav1.5 independent of CaM.
Another study reported that the binding of CaM to the Nav1.5 C-terminal domain
modulated the interaction between the C-terminal domain and the inactivation gate (IIIIV linker) of Nav1.5 (Kim et al., 2004), and presented data against the direct binding
between Ca2+ and the C-terminal domain of Nav1.5. The mechanism for the regulation of
Nav1.5 by Ca2+-dependent CaM thus remains to be further explored.

1.3.5.3. Nedd4 and SGKs
The ubiquitin-protein ligase Nedd4-2 was shown to interact directly with the PY
motif (xPPxY) of Nav1.5 (van Bemmelen et al., 2004), and may be involved in regulation
of membrane turnover of Nav1.5 by ubiquitination. Co-expression of the ubiquitinprotein ligase Nedd4 in Xenopus oocytes decreased the peak sodium current in wild type
Nav1.5, but not the channel with mutated PY, suggesting that Nedd4 down-regulated
cardiac channel abundance by direct interaction with the PY domain at the C-terminus
(Abriel et al. 2000). In a detailed study, human Nedd4-2 (homolog to Xenopus oocytes
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Nedd4) decreased the expression of Nav1.5 on cell membrane by ubiquitination (van
Bemmelen et al., 2004). Further studies revealed that the effects of Nedd4 on Nav1.5
could be related to the serum and glucocorticoid–inducible kinases SGK1 and SGK3.
Coexpression of wild type SGK1 and constitutively active S422DSGK1 in Xenopus oocytes
reversed the suppression of the endogeneous Nedd4 by phosphorylation, and thus
modulated channel abundance in the plasma membrane and enhanced the peak sodium
current. In contrast, coexpression of SGK3 may have influence on the gating properties
of Nav1.5 directly, not by inactivation of Nedd4 (Boehmer et al. 2003). In addition,
phosphorylation of Nedd4-2 induced the degradation of SGK (Zhou et al., 2005). The
degradation and internalization of Nav1.5 on cell membrane deserved further studies.

1.3.5.4. Syntrophin/dystrophin
Syntrophins are a family of intracellular adaptors contained in the large
dystrophin-associated protein complexes (Ou et al. 2003). Syntrophin 2 has been shown
to be involved in regulation of Nav1.5 mechanosensitivity and channel kinetics through
interaction between the PDZ domain of syntrophin 2 and the C-terminus of Nav1.5 (Ou
et al. 2003). The increased peak inward sodium current was detected in response to bath
perfusion, which was used to assess the mechanosensitivity of the sodium channel,
whereas the perfusion-induced increase in sodium currents was abolished by the
introduction of a PDZ binding domain containing peptide (Ou et al. 2003).

Co-

transfection of Nav1.5 and syntrophin 2 reduced the availability of sodium channel and
changed channel activation and inactivation kinetics (Ou et al. 2003). A recent study
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suggested that dystrophin together with syntrophin are part of a multiple protein complex
that modulated the expression level and function of Nav1.5 (Gavillet et al. 2006).

1.4. Rationale and objectives
Nav1.5 is a key protein invovled in generation and propagation of the cardiac
action potential.

Nav1.5 mutations were demonstrated to cause lethal arrhythmias

including LQTS, Brugada syndrome and PCCD. However, many questions remained to
be answered. First, when this thesis project first began, the only known protein that could
modulate the function of Nav1.5 was the β1-subunit. Are there other proteins that can
interact with and regulate the function of Nav1.5? Does Nav1.5 function in a large protein
complex? Second, the molecular mechanisms by which Nav1.5 mutations cause LQTS
were not well-defined in vivo. Do LQTS mutations cause re-modeling of gene expression
in the heart? Third, is Nav1.5 expressed in other tissues and does it play a role in other
tissues or organs? To address these questions, I initiated three studies. Thus, this thesis
covers three interesting areas on Nav1.5. Chapter II concerns the regulation of Nav1.5
function. I have identified a new regulatory protein, MOG1, that modulates the function
of Nav1.5. In Chapter 3, I tested the hypothesis that LQTS mutations cause remodeling of
gene expression in the heart. Genes whose expression is significantly altered by
transgenic overexpression of one LQTS mutation in the mouse heart have been identified.
Studies on Nav1.5 are also expanded into non-cardiac tissues in searching for novel roles
it may play. Thus, in Chapter 4, I investigated the localization of Nav1.5 in the mouse
brain to explore the possible novel roles Nav1.5 may play in the brain. These studies on
Nav1.5 are expected to help us understand how the function of Nav1.5 is regulated, how
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Nav1.5 mutations cause life-threatening cardiac diseases and provide insights into the
pathogenetic molecular mechanism of cardiac arrhythmias. They will also shed light on
the new functions that Nav1.5 may play.
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CHAPTER II.
IDENTIFICATION OF A NOVEL PROTEIN THAT INTERACTS WITH AND
REGULATES THE FUNCTION OF CARDIAC SODIUM CHANNEL NAV1.5:
MOG1 INCREASES SODIUM CURRENTS1

2.1 ABSTRACT
The cardiac sodium channel α subunit Nav1.5 plays an important role in the
generation and propagation of electrical signals in the heart, and can cause cardiac
arrhythmias, heart failure and sudden death when mutated or deregulated. However, the
precise composition of the multi-protein complex for the channel has not been completely
defined. Here we report that the physiological function of Nav1.5 is regulated by MOG1,
a small protein highly conserved from yeast to humans. Although MOG1 has been
implicated in nuclear trafficking of proteins, its localization in cytoplasm and potential
interaction with a yeast membrane-associated sensor Sln1p suggest that the in vivo
physiological roles of MOG1 need to be further defined. Yeast two-hybrid screening
with the Nav1.5 identified MOG1 as an interactor. The interaction was confirmed by in
1

Most of the data in this chapter are in press as Wu L et al. (2008) Journal of Biological Chemistry
283:6968-78. However this chapter has been rewritten for the purpose of this dissertation.
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vitro GST pull-down and in vivo co-immunoprecipitation assays.

Co-expression of

MOG1 with Nav1.5 in HEK293 cells increased sodium current densities, whereas knockdown of the expression of MOG1 by siRNA in HEK293 cells with stable expression of
Nav1.5 revealed a significant reduction of the amplitude or complete abolition of sodium
currents.

The results were replicated in neonatal mouse ventricular myocytes.

Immunostaining studies revealed that in the heart, MOG1 was expressed in both atrial
and ventricular tissues with predominant localization at the intercalated discs. These
results indicate that MOG1 is a critical regulator of sodium channel function in the heart
and reveal a new function for MOG1. This study further demonstrates the functional
diversity of Nav1.5-binding proteins, which serve important functions for Nav1.5 under
different cellular conditions.

2.2 INTRODUCTION
The SCN5A gene encodes Nav1.5, the α-subunit of the cardiac sodium channel
which plays an important role in generating the cardiac action potential and mediating the
rapid conduction of electrical impulses through cardiac tissues. Mutations in the cardiac
sodium channel have been identified in several important human diseases including long
QT syndrome, Brugada syndrome, idiopathic ventricular fibrillation, cardiac conduction
defects, and dilated cardiomyopathy associated with atrial fibrillation (Wang et al. 1995,
Chen et al. 1998, Schott et al. 1999, Tan et al. 2001, Olson et al. 2005).
Due to its critical importance in cardiac physiology and human disease, studies to
define the regulatory proteins and other components of Nav1.5 associated complex have
been of great interest. The major component of the sodium channel complex is the pore-
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forming α-subunit that consists of four homologous domains (DI, DII, DIII, and DIV),
each of which contains six transmembrane segments (S1-S6) (Gellens et al. 1992, Wang
et al. 1996). The channel complex contains other subunits, including at least four βsubunits identified thus far. Co-expression of the β1-subunit with Nav1.5 caused a small
but significant acceleration of the recovery from inactivation as well as an increase in
current density which may be due to an increased targeting efficiency of the mature
channel to the cell membrane (Nuss et al. 1995, Qu et al. 1995). The β3 subunit caused a
depolarizing shift in steady-state inactivation and a slower recovery from inactivation
than the β1-subunit (Fahmi et al. 2001).

The β2 subunit was shown to cause a

hyperpolarizing shift in Nav1.5 gating (Johnson et al. 2006). A mutation in the β4
subunit was reported to increase the late sodium current associated with long QT
syndrome (Medeiros-Domingo et al. 2007).
In addition to the β subunits, other accessory proteins have been identified for
Nav1.5. Their interactions have been shown to form a multi-protein complex (Abriel et al.,
2005). Lemaillet et al. demonstrated that a 9-amino acid motif in the cytoplasmic loop II
conserved through vertebrate sodium channels is responsible for binding to ankyrin G
and the localization of sodium channel to cell membrane (Lemaillet et al. 2003). The Cterminus of Nav1.5 contains 244 amino acid residues that have been shown to be
important for interactions with proteins such as FHF1B (fibroblast growth factor
homologous factor 1B), calmodulin (CaM), Nedd4-like ubiquitin-protein ligases,
syntrophin, Fyn, and protein tyrosine phosphatase (PTPH1) (Abriel H et al. 2005,
Jespersen T et al. 2006). In a recent study, 14-3-3 was found to interact with the
cytoplasmic loop I between DI and DII and its dimerization was needed for regulation of
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sodium currents (Allouis M et al. 2006). Despite the diversity in accessory proteins, the
composition of the cardiac sodium channel complex remains poorly understood. It is
reasonable to expect that many more proteins are involved in the dynamic networks of
protein-protein interactions with Nav1.5 and underscores the significance of multi-protein
complexes that are critical for normal cardiac function.
Finding new Nav1.5-associated proteins in myocyte ionic homeostasis was
expected to provide an explanation for the disruption of cardiac conduction system that
leads to arrhythmias and sudden death. To identify new proteins associated with the
cardiac sodium channel complex, we performed a yeast two-hybrid screen with separate
intracellular domains of Nav1.5 as baits. When the cytoplasmic loop II between DII and
DIII was used as the bait, a candidate Nav1.5-interacting protein, MOG1, was identified.
MOG1 was initially identified as a suppressor that was able to rescue the
temperature-sensitive

defect

of

S.

cerevisiae

Ran,

a

protein

involved

in

nucleocytoplasmic transport, microtubule and nuclear assembly, and the spatial and
temporal organization of the eukaryotic cell (Oki et al. 1998, Quimby et al. 2003). In
vitro studies showed that MOG1 can bind to Ran-GTP (Oki et al. 1998), and release GTP
(Steggerda et al. 2000), but its in vivo function is not clear. MOG1 has been shown to be
a highly conserved protein from yeast to humans (Marfatia et al. 2001). Human MOG1
gene contains 5 exons and 4 introns and encodes a protein of 187 amino acids with a
calculated molecular weight of 20 kDa (Marfatia et al. 2001). The highest expression of
MOG1 was detected in the heart by Northern blot analysis (Marfatia et al. 2001),
However, the exact physiological function of MOG1 remains to be studied. Our finding
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that MOG1 interacts with Nav1.5 suggests that MOG1 may play a role in cardiac
physiology.
We further demonstrated the interaction between MOG1 and Nav1.5 by both in
vitro GST-pull-down and in vivo co-immunoprecipitation assays. We examined the
physiological role of MOG1 by co-expression of MOG1 and Nav1.5 in HEK293 cells and
neonatal cardiomyocytes. Our results indicate that MOG1 is a co-factor for Nav1.5 and
modulates the appropriate expression and function of Nav1.5.

2.3 MATERIALS AND METHODS
Construction of Plasmids and Antibodies
The human MOG1 gene was cloned into vector pET28a at the EcoR I and Sal I
sites (pET28a-MOG1) as previously described (Marfatia et al., 2001). The MOG1 insert
was released from pET28a-MOG1 and subcloned into pcDNA3.1C (Invitrogen) at the
BamH I and Not I sites or into pCMV10, yielding mammalian expression constructs for
His-tagged MOG1 (pcDNA3.1C-MOG1) and Flag-tagged MOG1 (pCMV10-MOG1),
respectively.
Human cardiac sodium channel gene SCN5A was cloned into vector pcDNA3
(pcDNA3-Nav1.5) as described (Wan et al., 2000, Wan et al., 2001), and used for
establishing a stable HEK293 cell line with constant expression of Nav1.5, (hereafter
referred to as “HEK293/Nav1.5”; a generous gift from Dr. Glenn E. Kirsch).

The

cytoplasmic loop II (LII) between transmembrane domains DII and DIII of Nav1.5 was
amplified by PCR using oligos containing Xho I and EcoR I restriction sites (Forward: 5’AGAATTCAGCTCCTTC

AGTGCAGA-3’,
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Reverse:

5’-TCTCGAGTTAGTGGT

AGCAGGTCTT-3’) and cloned into vector pGEX4T-1-GST-tag (Novagen) (pGEX4T-1GST-Nav1.5-LII) for expression and purification of GST-Nav1.5-LII fusion protein. The
cytoplasmic loop I (LI) between DI and DII of Nav1.5 was amplified and cloned using an
identical approach to generate pGEX4T-1-GST-Nav1.5-LI for expression and purification
of GST-Nav1.5-LI fusion protein.

Primers used to amplify the Nav1.5-LI are 5’-

AGTTCAGGATCCGAGGAGCAAAA-3’ and 5’-CTTACAGCGGCCGCTTACTTCA
CTCCCT-3’. Nav1.5-LII was also sub-cloned into pcDNA3.1A to express His-tagged
Nav1.5-LII (pcDNA3.1A-Nav1.5-LII) in mammalian cells.
Two anti-MOG1 antibodies were developed by Genemed Synthesis, Inc. The
first MOG1 antibody (#2738) was developed with a MOG1-specific peptide, CQPPPDNRSSLGPENL at the N-terminal section, and the immunogen for the second
antibody (#3350) was a peptide, C-NQQVAKDVTLHQALLRLPQYQTDL at the Cterminal section. The rabbit polyclonal anti-Nav1.5 antibody was developed as described
in chapter IV.

Yeast Two-Hybrid Screen
Yeast two-hybrid analysis was performed with a pre-made MATCHMAKER,
human heart cDNA library constructed in S. cerevisiae host strain, Y187 (ClonTech
Laboratories, Inc.). pACT2-derived constructs generate fusion proteins with the GAL4
activation domain (GAL4 AD) fused to a library of other proteins. The baits for library
screening were five different segments of Nav1.5 fused to GAL4-DNA binding domain
(GAL4 BD) in the pAS2 vector. As Nav1.5 is a membrane protein, the yeast two-hybrid
screen with the entire Nav1.5 protein is unlikely to be fruitful because the protein may not
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enter the yeast nuclei. Thus, we selected five cytoplasmic segments of Nav1.5 as baits.
These include the N-terminal domain (amino acids 1 to 123), cytoplasmic loop I between
DI and DII (Nav1.5-LI, amino acids 437 to 711), cytoplasmic loop II between DII and
DIII (Nav1.5-LII, amino acids 940 to 1200), the inactivation gate between DIII and DIV
(amino acids 1471 to 1523), and the C-terminal domain (amino acids 1773 to 2016). A
bait plasmid was transfected into yeast strain Y187 with a library of human heart cDNAs
fused to GAL4-AD. Positive colonies were identified as instructed by the manufacturer
(ClonTech Laboratories, Inc.). Approximately 107 primary transformants were screened
for each of the baits. DNA was isolated from each positive clone and used to transform E.
coli HB101 (Leu-) to isolate only pACT2 derivative plasmids. The cDNA insert from
each positive pACT2 derivative clone was amplified by PCR and sequenced by the
BigDye Terminator v1.1 Cycle Sequencing kit and an ABI PRISM 3100 Genetic
Analyzer. The DNA sequences were then characterized by Blast analysis against the
NCBI database to determine the identity of the potential Nav1.5-interacting proteins.

GST Pull-down Assays
Construct pGEX4T-1-GST, pGEX4T-1-GST-Nav1.5-LI, or pGEX4T-1-GSTNav1.5-LII was transformed into E. coli BL21 to express the GST, GST-Nav1.5-LI, and
GST-Nav1.5-LII proteins. The GST and GST-fusion proteins were then affinity-purified
using glutathione sepharose 4B beads according to the manufacturer’s protocol
(Amersham Pharmacia Biotech). The proteins were eluted with 0.01 M glutathione/100
mM Tris-HCl, pH 7.5, and dialyzed in dialysis buffer (20 mM Tris-HCl, pH 7.5, 50 mM
NaCl, 0.1 mM EDTA, 20% glycerol, and 0.5 mM DTT).
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The [35S]-labeled MOG1 protein was prepared using a TNT Quick Coupled
Transcription/Translation system (Promega). Briefly, 1 µg of plasmid DNA was mixed
with TNT Quick Master mix and [35S]-methionine, and incubated for 90 minutes at 30°C.
The [35S]-labeled MOG1 protein was mixed with GST, GST-Nav1.5-LI, or GST-Nav1.5LII immobilized on glutathione sephrose 4B beads in binding buffer (1 mM DTT, 0.5
mM PMSF, 1 mM EDTA, 20 mM Tris-HCl, 150 mM NaCl, 0.1% Triton X-100), and
incubated for 2-3 hours at 4°C. After binding, the beads were washed with binding buffer,
and bound proteins were eluted with 1X SDS loading buffer, separated on a 12% SDSpolyacrylamide gel, dried, and visualized by exposing to X-ray film at -80°C for 12 hours.

Co-Immunoprecipitation (co-IP) Analysis
HEK293/Nav1.5 cells were maintained in Dulbecco’s minimum essential medium
(DMEM) supplemented with 10% heat inactivated fetal bovine serum (Invitrogen) and
transfected with 10 µg of pcDNA3.1C-MOG1 DNA for the expression of His-tagged
MOG1 with Lipofectamine 2000 (Invitrogen). Transfection was carried out with 80%
confluent cells in a 10 cm plate. Harvested HEK293 cells/cardiomyocytes were lysed in
the TNEN buffer (50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 2.0 mM EDTA, 1.0%
Nonidet P40, protease inhibitor cocktail (Roche Molecular Biochemicals Complete
Solution) for 24 to 48 hours after transfection. 500 µg of total cell extracts was mixed
with a rabbit polyclonal anti-Nav1.5 antibody (Wu et al., 2002) and incubated on a rotator
for 3 hours at 4°C. Protein A/G sepharose 4B beads (Sigma-Aldrich) were added and
incubation was continued for another 2 hours. The bound proteins were eluted by boiling
the samples for 5 minutes in 1X SDS loading buffer, separated by SDS-PAGE, and
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transferred onto a nitrocellulose membrane. The membrane was probed with an anti-His
antibody (Sigma-Aldrich) recognizing His-MOG1 fusion protein, and the protein signal
was visualized by enhanced chemiluminescence according to the manufacturer's
instructions (Amersham Biosciences). For reverse co-IP, a rabbit polyclonal anti-MOG1
antibody was used for immunoprecipitation and the anti-Nav1.5 antibody was used for
Western blot analysis. Similar co-IP studies were performed to study the interaction
between the cytoplasmic loop II of Nav1.5 and MOG1 by co-expressing His-tagged
Nav1.5-LII and Flag-tagged MOG1 in HEK293 cells and with an anti-His antibody and
an anti-Flag antibody.
For co-immunoprecipitation analysis of MOG1 and Nav1.5 in cardiac cells, total
protein lysates were isolated from adult mouse hearts. Mice were sacrificed and the
hearts were excised, washed in Hanks buffer, cut into pieces, add lysed in the lysis buffer
(20 mM Tris-HCl, pH7.4, 1 mM EDTA, 150 mM NaCl, 1% NP-40, cocktail of protease
inhibitors).

The lysates were sonicated on ice (Sonicator 3000, Misonic Inc, NY),

incubated on ice for 30 min, and then microcentrifuged at 40C for 10 min.

The

supernatant was collected and its concentration was measured using the BioRad Protein
Assay dye. The lysates were pre-cleared on protein A/G beads at 4 °C for 40 min prior to
co-IP studies. Protein A/G beads (40 µl) were incubated with 2 µg of the anti-Nav1.5 (or
anti-MOG1) (1:500 dilution in PBST) and 500 µg of cell lysates with gentle rocking for 2
h at 4 °C. After washing five times with washing buffer (PBS buffer, protease inhibitors,
and 0.5% Triton X-100), the immunoprecipitates were subjected to SDS-PAGE and
immunoblot analysis using the anti-MOG1 antibody (or anti-Nav1.5).

Cell lysates

incubated with protein A/G beads alone were used as a negative control. Co-IP of lysates
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with normal IgG was also used as a negative control in each experiment. Studies were
repeated at least three times.

Isolation of Mouse Cardiomyocytes
For isolation of neonatal mouse cardiomyocytes, 10-15 mouse hearts were
collected from 3-day-old CBA/B6 mouse neonates. The ventricles were excised and
myocytes were isolated using the Neonal Rat/Mouse Cardiomyocyte Isolation kit from
CELLUTRON Life Technology. The cells were plated on uncoated 100 mm plates to
reduce the contamination of cardiac fibroblasts. Myocytes were then cultured in the NS
medium (CELLUTRON Life Technology) supplemented with 10% FBS. Isolation of
adult cardiomyocytes was performed as previously described by us (Tian et al., 2004,
Yong et al., 2006, Yong et al., 2007). The heart was isolated from a mouse (6-8 months)
and mounted on a Langendorff apparatus for retrograde perfusion in calcium-containing
buffer (in mM): 118, CaCl2; 2.5 MgCl2; NaCl; 4.8, KCl; 2, 1.2 KH2PO4; 11, glucose;
13.8, NaHCO3; 4.9, pyruvic acid; pH 7.2–7.4, with 95% O2:5% CO2; at 37 °C. The
calcium free buffer was then replaced and 0.5 mg/ml collagenase was added for digestion
(Type II, Worthington). After 30 minutes of digestion, cells were collected for further
studies.

Immunohistochemistry
Immunostaining was performed on adult cardiomyocytes or frozen heart sections (6 µm)
with polyclonal anti-Nav1.5 and anti-MOG1 antibodies. Briefly, a freshly excised mouse
heart was embedded in Tissue-TEK O.C.D. Compound (Ted Pella, Inc.CA) and frozen in
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liquid nitrogen. The frozen sections were pretreated with hydrogen peroxide. The
cardiomyocytes were pretreated with 2% Triton-X100. The pretreated section or the
cardiomyocytes were then blocked in blocking buffer (5% bovine serum albumin and
0.3% Triton X-100 in 1x PBS) for 2 hr, and then incubated with the primary antibody
(1:250 dilution) at 4°C for 24 hours. The sections were then incubated with a secondary
antibody mixture containing the FITC-conjugated and Texas Red-conjugated secondary
antibodies at room temperature for 2 hours. The immunostained slides were mounted
with anti-fading media, and visualized under a confocal microscope.

RNA Interference Analysis
MOG1-specific siRNAs were synthesized by Dharmacon RNA Technologies.
Two siRNAs were targeted to mouse MOG1 and their sequences were: siRNA1, 5’GAGCCUGAGUAACUUUGAAdTdT-3’ and siRNA2, 5’-UAACUAGUUUGACU
CUUCAdTdT-3’.

Blast analysis against the NCBI database suggests that the two

siRNAs are specific to MOG1 and do not match any other genes in the mouse genome.
The control scrambled siRNA sequences were selected by GenScrip. The sequences for
scrambler siRNAs were 5’-UCAUGCCAUUCUUAGUAAU dTdT-3’ for siRNA1, and
5’-CGAUAGU TTCTUGUCTGGAdTdT-3’ for siRNA2. The siRNAs were labeled with
fluorescein at the 5’-end. The siRNAs were transfected into cells by oligofectamine
(Invitrogen). Cells were incubated for another 48 hours for expression and functional
studies.

Quantitative Real-Time (RT)-PCR Analysis
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Total RNA was isolated from siRNA-treated cells using TRIzol reagent
(Invitrogen). Reverse transcription was performed using the SuperScript Choice System
(Invitrogen).

Quantitative RT-PCR was performed with SYBR Green (Applied

Biosystems) with an ABI Prism 7900HT Sequence Detection System. 18S rRNA was
used as an internal control. The relative mRNA expression level of MOG1 was indirectly
shown as CT values (threshold cycle or the fractional cycle number at which the amount
of amplified target reaches a fixed threshold). The CT values were then normalized by
the RT program as previously described (Tan et al. 2002). Briefly, the target PCR CT
value subtracts 18S PCR CT value to yield the ∆CT value, and this value is then adjusted
to the mean ∆CT value of untreated cells, generating the ∆∆CT value. The relative
mRNA expression level for each sample was then calculated using the following equation:
relative mRNA expression = 2-∆∆CT (Tan et al. 2002).

Electrophysiological Analysis
HEK293/Nav1.5 cells or neonatal cardiomyocytes were transfected with
pcDNA3.1C-MOG1 using Lipofectamine 2000 (Invitrogen) and electrophysiological
recordings were performed as described previously (Tian et al., 2004, Yong et al., 2007).
Vector pIRE-GFP DNA expressing green fluorescent GFP protein (0.25 µg) was cotransfected together with pcDNA3.1C-MOG1 to serve as an indicator (Wan et al., 2001,
Wu et al. 2002). Only GFP-positive cells were selected for recording sodium currents.
Cells with successful transfection of siRNAs were also identified by the green color as
the siRNAs were labeled with fluorescence at the 5’-end. Pipettes were fabricated from
boroscillate glass (FHC, Inc.) and electrode resistance ranged from 2-3 MΩ when filled
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with pipette solution with the following composition (in mM): NaCl, 20; CsCl, 130;
HEPES, 10; EGTA, 10; pH 7.2 with CsOH. Voltage command pulses were generated
using the Multipatch 700B amplifier (Axon Instruments) under the control of a desktop
computer with pCLAMP software (9.0, Axon Instruments). Currents were filtered at 5
kHz (-3 dB, 4-pole Bessel filter) following series resistance compensation. The holding
potential for all pulse protocols was -100 mV and experiments were performed at room
temperature (22°C). For HEK293 cells, the composition of the bath solution was (in
mM): NaCl, 70; CsCl, 80; KCl, 5.4; CaCl2, 2; MgCl2, 1; HEPES, 10; glucose, 10; pH 7.3
with CsOH. For neonatal cells, the NaCl concentration was reduced to 20 mM and CsCl
was increased to 120 mM for better voltage control. To reduce contaminating Ca2+ and
K+ (transient outward) currents, 2 mM CdCl2 and 2 mM 4-AP, respectively, were added
to the bath.

Western blot analysis
To determine the expression level of the Nav1.5 protein in the membrane fraction,
total protein lysates were extracted from HEK293/Nav1.5 cells transiently transfected
with pcDNA3.1C-MOG1 or empty vector pcDNA3.1C as control using the lysis buffer
(1% Triton-100, 150 mM NaCl, 50 mM Tris-HCl, pH7.5, 1 mM EDTA, a protease
inhibitor cocktail). Membrane fractions were isolated by centrifugation at 40,000 rpm
followed by another centrifugation at 14,000 rpm.

The final pellet contains the

membrane protein fraction and the supernatant contains the cytosolic protein fraction.
Equal amounts of protein extracts were separated on SDS-PAGE. Western blot analysis
was performed as described previously (22). A rabbit polyclonal anti–Nav1.5 was diluted
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in 1:500 in 0.3% BSA in PBST, and used in Western blot analysis. The signal was
detected using enhanced chemiluminescence (ECL kit, Amersham Biosciences,
Buckinghamshire,UK). An anti-KCNQ1 antibody (Santa Cruz Biotechnology) was used
as a loading control at 1:500 dilution in PBST.
Statistical Analysis
Data are represented as mean values ± SEM. Statistical analysis was performed
using an ANOVA and two-tailed Student’s t-test to compare means. Significance was set
at the indicated P values.

2.4 RESULTS

MOG1 was identified as a candidate protein that interacts with Nav1.5 by a yeast
two-hybrid screen
To identify proteins that interact with Nav1.5, we carried out a yeast two-hybrid
screen. We screened a human cardiac pre-transformed MATCHMAKER cDNA library
(ClonTech, Inc.).

Five cytoplasmic segments of Nav1.5 were used as baits for the

screening and these include the N-terminus, loop I (between DI-DII), loop II (between
DII–DIII), loop III (between DIII–DIV), and C-terminus. The Nav1.5 C-terminus-GAL4BD fusion protein alone activated transcription of reporter genes, thus no further
screening was performed with this bait. No positive clones were obtained with the Nterminal domain and cytoplasmic loop I baits. There were 223 positive clones obtained
with the cytoplasmic loop II bait, and 29 positive clones with the loop III bait (Appendix
B). One positive clone from the screening was found to encode the portion of MOG1
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(GenBank Accession# AF265206, amino acids 65 to 186), and was independently
identified twice from the library screening.

Interaction between MOG1 and Nav1.5 as shown by GST pull-down
To further evaluate the interaction between MOG1 and Nav1.5, we carried out a
GST pull-down assay. The cytoplasmic loop II of Nav1.5 (amino acids 940 to 1200) was
fused to GST (GST-Nav1.5-LII), expressed in E. coli, and purified.

Radioactively-

labeled MOG1 protein was prepared by in vitro transcription followed by translation
using
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S-methionine and this appeared as a single band of 28 kDa (Fig. 2.1A, lane 1).

The GST-Nav1.5-LII fusion protein successfully pulled down

35

S-MOG1 in the assay

(Fig. 1A, lane 2), whereas two negative controls, GST alone (Fig. 2.1A, lane 4) and the
GST-Nav1.5 cytoplasmic loop I fusion protein (GST-Nav1.5-LI, Fig. 2.1A, and lane 3)
failed to interact with
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S-MOG1. These results suggest that MOG1 interacts with the

cytoplasmic loop II of Nav1.5 in vitro.

Interaction between MOG1 and Nav1.5 as shown by co-immunoprecipitation
HEK293/Nav1.5 was transfected with pcDNA3.1C-His-MOG1.

Cell extracts

were immunoprecipitated using an antibody against MOG1 (Fig. 2.2A, lane 3) or with
control rabbit pre-serum IgG (Fig. 2.2A, lane 2). The bound proteins were then detected
by Western blot analysis with an anti-Nav1.5 antibody. The anti-MOG1 antibody, but not
the control IgG, precipitated a 250 kDa Nav1.5 protein.
immunoprecipitation was also performed.

Reciprocal co-

The anti-Nav1.5 antibody was used for

immunoprecipitation, and the anti-MOG1 antibody was used for Western blot analysis.
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MOG1 protein was successfully precipitated by the anti-Nav1.5 antibody, but not by the
rabbit pre-serum control (Fig. 2.2B). The interaction between Nav1.5 and MOG1 was
also evaluated in cardiomyocytes. Nav1.5 was immunoprecipitated by an anti-MOG1
antibody (Fig. 2.2E) and MOG1 was precipitated by an anti-Nav1.5 antibody (Fig. 2.2F).
These results support the interaction between MOG1 and Nav1.5.
The interaction between MOG1 and Nav1.5 was further confirmed in mouse
cardiac cells. Total protein extracts were prepared from mouse hearts. Both MOG1 and
Nav1.5 proteins are abundantly expressed in cardiac cells, and can be easily detected by
Western blot analysis (lanes 1 in Fig. 2E and lane 1 in Fig 2F). Two protein bands were
detected for MOG1, which may represent the two MOG1 isoforms derived from
alternatively spliced transcripts as reported previously by Marfatia et al (Marfatia et al
2001).

Mouse cardiac protein extracts were precipitated either with a polyclonal

antibody against MOG1 (Fig. 2E, lane 2) or with control IgG (Fig. 2E, lane 3). The
bound proteins were then detected by immunoblot analysis with an anti-Nav1.5 antibody.
The MOG1 antibody easily precipitated a Nav1.5 protein (Fig. 2E, lane 2). Similar
experiments revealed that the anti Nav1.5 antibody could precipitate MOG1 proteins from
mouse cardiac cell extracts (Fig. 2E, lane 2). These results indicate that MOG1 interacts
with Nav1.5 in vivo in cardiac cells.
As MOG1 was pulled out from the yeast two-hybrid library using Nav1.5-LII, we
next determined whether the loop II interacts with MOG1 using the coimmunoprecipitation assay. HEK293 cells were transiently co-transfected with
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Fig. 2.1. GST pull-down assay for the interaction between Nav1.5 and MOG1. A).
Coommassie staining for purified GST and GST fusion proteins. B). In vitro-translated
35
S-MOG1 bound strongly to Nav1.5 cytoplasmic loop II fused to GST (GST-Nav1.5-LII;
lane 2), but not to cytoplasmic loop I fused to GST (GST-Nav1.5-LI; lane 3) or GST
alone (lane 4). Lane 1, one-tenth of the input (35S-MOG1).
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Fig. 2.2. Co-immunoprecipitation assay for the interaction between Nav1.5 and
MOG1. A, Whole cell lysates prepared from HEK293/Nav1.5 cells transiently
transfected with a pCMV-10-MOG1 construct were immunoprecipitated with an antiMOG1 antibody (lane 3) or pre-serum (lane 2) and analyzed by Western blotting with a
polyclonal anti-Nav1.5 antibody. The anti-MOG1 antibody successfully precipitated
Nav1.5.
Lane1, one-tenth of the input (cell extracts). B, Reciprocal coimmunoprecipitation with an anti-Nav1.5 antibody for immunoprecipitation and the antiMOG1 antibody for Western blotting. Lane 3, one-tenth of the input (cell extracts). C,
Interaction between His-tagged loop II of Nav1.5 and Flag-tagged MOG1 co-transfected
into HEK293 cells. An anti-His antibody successfully precipitated Flag-tagged MOG1
(lane 2), but the control mouse serum failed to precipitate Flag-tagged MOG1. Lane 1,
1/50 of the input (cell extracts). D, Reciprocal co-immunoprecipitation for C. Lane 1,
control mouse serum failed to precipitate His-tagged Nav1.5-LII; lane 2, an anti-Flag
antibody successfully precipitated His-tagged Nav1.5-LII; lane 3, 1/50 of the input (cell
extracts). E. Protein lysates extracted from mice cardiac cells were immunoprecipitated
with an anti-MOG1 antibody (lane2) and control serum (lane3). Lane 1, one-fifth of
input. Signals were detected with an anti-Nav1.5 antibody. F. Reciprocal coimmunoprecipitation with an anti-Nav1.5 antibody for immunoprecipitation and the antiMOG1 antibody for Western blotting. Lane 1, one-fifth of input. Lane 2,
immunoprecipitation with anti-Nav1.5. Lane 3, immunoprecipitation with control serum.
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LII (pcDNA3.1A-Nav1.5-LII).

Cell extracts were immunoprecipitated using a

monoclonal antibody against His or with control IgG. The bound proteins were then
detected by Western blot analysis with a monoclonal anti-Flag antibody. The anti-His
antibody, but not the control IgG, precipitated Flag-tagged MOG1 (Fig. 2.2C). A coimmunoprecipitation

assay

was

performed

using

an

anti-Flag

antibody

for

immunoprecipitation. Nav1.5-LII fusion protein was successfully precipitated by the
anti-Flag antibody, but not by control mouse serum IgG (Fig. 2.2D).

These

coimmunoprecipitation results indicate that the association of MOG1 to Nav1.5 is
mediated by the cytoplasmic loop II of Nav1.5.

MOG1 increases sodium current density in a mammalian expression system
We wished to determine whether the interaction of MOG1 with Nav1.5 modified
channel function. For this purpose, we expressed MOG1 in HEK293/Nav1.5 cells and
measured whole-cell sodium currents. As shown in Fig. 2.3A and 2.3B, the sodium
current density (expressed as peak current normalized to cell capacitance, pA/pF) across
the range of test potentials was significantly increased in cells co-expressed with MOG1.
The maximum current density normally measured at -30 mV for vector cells was shifted
to -35 mV and increased by 61 pA/pF when co-expressed with MOG1. This is despite
the fact that co-expression with MOG1 did not alter cell capacitance (16.6 ± 4.1 pF, n = 5
versus 18.6 ± 1.9 pF, n = 9). Steady-state activation and inactivation gating properties
were evaluated using the pulse protocols shown in the insets (Fig. 2.3C). The data for
channel activation are the mean normalized conductance plotted against the test potential.
MOG1 shifted the voltage dependence of activation to more negative potentials by 4 mV
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Fig. 2.3. Over-expression of MOG1 in HEK293/Nav1.5 cells increased sodium
current density. A, Raw traces for sodium currents with (right) and without (left) overexpression of MOG1 that were elicited with the current protocol depicted in the inset. B,
For activation, cells were held at -100 mV and depolarized in 5 mV increments. The
current-voltage relationship for both cell groups is summarized with current amplitudes
normalized to cell capacitance (pA/pF, abscissa). Both steady-state activation and
inactivation were determined by fitting the peak currents with a Boltzman distribution:
I/Imax = 1/(1+e((-V-V1/2)/s)), where I is the current at test potential V, Imax is the
maximum current, V1/2 is the potential giving the half-maximum current; see Text for
fitting parameters. C, Steady-state activation (right) and inactivation curves (left).
Steady-state activation was plotted over the indicated voltage range and expressed as the
current at the test potential over the maximum current (I/Imax, abscissa). A two-pulse
protocol was used to estimate the membrane potential dependence of inactivation. Cells
were stepped to conditioning potentials for 500 ms as shown on the abscissa before
depolarization to -20 mV (50 ms step) and peak sodium current from the test potential
was normalized to peak sodium current in the absence of a conditioning step. D,
Recovery from inactivation was assessed for both cell groups utilizing a two-pulse
protocol and the fractional current (P2/P1) was plotted against inter-pulse duration
between P1 and P2. The fraction of channels that had recovered following various time
intervals was calculated by dividing the peak current measured during a test pulse to -20
mV. The average data were fitted with a bi-exponential function: I/Imax = A1x(1-e(t/τ1))+A2x(1-e(-t/τ2)). In cells over-expressing MOG1, no effects in the inactivation
kinetics were observed but a hyperpolarizing 4 mV shift was detected in channel
activation.
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(V1/2act = -49.1 ± 0.1 mV, n = 5 versus -45.1 ± 0.2 mV, n = 9, P<0.05). A two-pulse
protocol was used to estimate the membrane potential dependence of inactivation. Cells
were stepped to conditioning potentials for 500 ms as shown on the abscissa before
depolarization to -20 mV (50 ms step) and the peak current from the test potential was
normalized to peak sodium current in the absence of a conditioning step.

Cells

expressing MOG1 showed no difference in the inactivation kinetics of Nav1.5 (Fig. 2.3C;
V1/2inact = -84.1 ± 0.1 mV, n = 5 versus -85.5 ± 0.1 mV, n = 7, P = NS). Similarly,
recovery from inactivation was not changed (Fig. 3D; t1/2 (τ1) = 4.2 ± 0.2 ms, n = 5 versus
3.8 ± 0.1 ms, n = 6, P = NS) as this was assessed using a two-pulse protocol and the
fractional current (P2/P1) was plotted against inter-pulse duration between P1 and P2.
These results show that MOG1 regulates the function of Nav1.5 by increasing sodium
current density and by modulating channel activation kinetics with a small
hyperpolarizing shift.

Knockdown of MOG1 Expression Reduced Sodium Current Density in a
Mammalian Expression System
Two MOG1-specific siRNAs were transfected into HEK293/Nav1.5 cells with
expression of MOG1. As shown in Fig. 2.4, Western blot analysis revealed that the
siRNAs were effective in knocking down MOG1 expression by around 80% compared to
cells treated with scramble siRNAs (18S rRNA was used as an internal control in these
experiments).

The knockdown of MOG1 expression was further confirmed with

quantitative RT-PCR analysis (data not shown). Sodium current density was reduced by
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Fig. 2.4. Effects of siRNAs on expression of MOG1. A, Knockdown of MOG1
expression was determined by Western blot analysis (β-actin as loading control). B, The
image from Western blot analysis was quantified and plotted. Two siRNAs and
corresponding scrambles were tested. siRNA1 and siRNA2 knocked down expression of
MOG1 by 4.2-fold and 3.9-fold, respectively.
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nearly 2-fold in siRNA-transfected HEK293/Nav1.5 cells (Fig. 2.5A, 2.5B) with no
alterations in the activation and inactivation kinetics (Fig. 2.5C, 2.5D). Cell capacitances
were no different between cell groups, 15.7 ± 1.3 pF (MOG1- siRNA) and 18.2 ± 1.4 pF
(scramble), P = NS. The kinetic parameters are as follows for MOG-siRNA versus
scramble: V1/2act = -46.3 ± 0.4 mV, n = 6 versus -49.3 ± 0.2 mV, n = 5, P = NS; V1/2inact =
-83.4 ± 0.2 mV, n = 6 versus -81.7 ± 0.2 mV, n = 5, P = NS; and t1/2 (τ1) = 7.1 ± 0.2 ms, n
= 6 versus 7.6 ± 0.3 ms, n = 5, P = NS. Therefore, reducing the endogenous expression
of MOG1 decreases sodium currents and suggests that MOG1 is required for the full
activity of cardiac sodium channels.

MOG1 and Sodium Current Density in Neonatal Cardiomyocytes
To determine the role of MOG1 in native cardiomyocytes, we studied the effects
of MOG1 on the function of Nav1.5 in neonatal mouse cardiomyocytes as in
HEK293/Nav1.5 cells. When MOG1 was over-expressed in 3-day neonatal myocytes,
sodium current density was increased by two-fold compared to control vector-transfected
myocytes with no apparent changes in cell capacitances (Fig. 2.6). Sodium currents were
elicited using a single pulse from -100 to -20 mV. Knockdown of MOG1 expression
with siRNAs in neonatal cells nearly eliminated the sodium currents (Fig. 2.7), while no
effects on the current were detected following transfection with siRNA scrambles 1 and 2.
These results show that in native cardiomyocytes, MOG1 exhibits a similar and
significant regulatory role on cardiac sodium channels as in HEK293 cells.
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Fig. 2.5. Knockdown of MOG1 expression by siRNAs in HEK293/Nav1.5 cells
decreased sodium current density. A, Raw traces of sodium currents in cells
transfected with a scramble (left) and a MOG1-specific siRNA1 (right). B, Effects of
MOG1-specific siRNA1 and control scramble siRNA on the current-voltage relationship
of Nav1.5. Identical results were obtained for siRNA2 (data not shown). C, D, The effect
of MOG1-specific siRNA1 on steady-state activation, inactivation, and recovery from
inactivation, respectively, was evaluated. The sodium currents were recorded and
analyzed as described in the Legend of Fig. 3.
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Fig. 2.6. MOG1 over-expression increases sodium current densities in neonatal
cardiomyocytes. Maximum currents were elicited using a single pulse from -100 to -20
mV and peak currents were expressed as current densities (pA/pF) and averaged for the
cell group. Cell capacitances (Cm) = 32.2 ± 4.7 pF (+ MOG1), 29.3 ± 2.8 pF (-MOG1).
“*” indicates P=1.5x10-5.
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Fig. 2.7. Effects of MOG1 siRNAs on sodium current densities in neonatal
cardiomyocytes. Maximum currents were elicited using a single pulse from -100 to -20
mV and peak currents were expressed as current densities (pA/pF) and averaged for the
cell group. Cm = 27.3 ± 3.1 pF (siRNA1), 30.4 ± 4.0 pF (siRNA2), 29.3 ± 3.1 pF
(scramble 1), 32.3 ± 2.2 pF (scramble 2). “*” indicates P=2.2x10-6, whereas “**”
indicates P=2.5x10-5.
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Strong expression of MOG1 at intercalated discs in cardiomyocytes and heart
tissues
The expression patterns of MOG1 in the heart was studied using immunostaining
with two independent anti-MOG1 antibodies. Peptide competition experiment was used
to evaluate the specifity of antibody.

Immunofluorescent signal was significantly

eliminated when the MOG1 antibody (with MOG1 antibody #2728) was pre-absorbed
with the antigen peptide (Fig. 2.8A and 2.8B). As shown in Fig. 2.8C, MOG1 was
widely expressed in both atrial and ventricular muscles (with MOG1 antibody #2728) and,
interestingly, this expression was highly localized in the intercalated discs. Similar
results were obtained with the second anti-MOG1 antibody (#3350; data not shown).
Immunostaining with a connexin 43 antibody made it possible to easily distinguish the
AV node from atrial and ventricular tissues (Fig. 2.8D).

Similar to connexin 43,

expression of MOG1 protein was high in atrial and ventricular tissues but low in AV
nodal tissues. Immunostaining studies were also performed in isolated mouse ventricular
myocytes and the results show that MOG1 expression was also particularly strong in the
intercalated discs. More importantly, the expression pattern of MOG1 was shown to
overlap with that of Nav1.5 in intercalated discs (Fig. 2.8E).

MOG1 Increases Cell Surface Expression of Nav1.5.
To investigate the potential mechanism by which MOG1 increases the sodium
channel density, Western blot analysis was performed with the membrane fraction and
cytoplasmic fraction of protein extracts isolated from HEK293/Nav1.5 cells transiently
transfected with MOG1 or empty vector (control). As shown in Fig 2.9A, Nav1.5
60
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Fig. 2.8. Expression profile of MOG1 protein in heart tissues and isolated
ventricular myocytes. MOG1 antibody specificity was examined in two adjacent tissue
slides (A and B). Atrial muscle was immunostained by an anti-MOG1 antibody (A) or
the MOG1 antibody preincubated with the peptide immunogen (B). scale bar=100 µm. C,
Strong expression of MOG1 in right atrium (RA) and right ventricle (RV) with relatively
lower expression in the distal common bundle or atrio-ventricular node (AV). D,
Immunostaining showing expression profile of connexin 43 (CX43). Scale bar=100 µm
E, Co-localization of MOG1 and Nav1.5 at intercalated discs in a cardiomyocyte. Adult
ventricular myocytes were isolated and double-stained with polyclonal anti-MOG1 (red)
and anti-Nav1.5 (green) antibodies. Nuclei were stained with DAPI (blue). Right panel
indicates the overlay of MOG1 and Nav1.5 images. Scale bar=10µm.
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Fig. 2.9. Co-expression of MOG1 increased cell surface expression of Nav1.5. A,
Western blot analysis with an anti-Nav1.5 antibody with the membrane fraction of protein
extracts from HEK293/Nav1.5 cells transfected with a MOG1 expression plasmid (+) or
the empty control vector (-). The membrane filter was later immunoblotted with an antiKCNQ1 antibody to ensure that an equal amount of proteins extracts were used in the
study. Overexpression of MOG1 increased the expression of Nav1.5 on cell membrane.
B, Similar studies as in (A), but the cytosolic fraction of protein extracts was analyzed.
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expression in the membrane fraction was increased with overexpression of MOG1 in
comparison with the control. Accordingly, Nav1.5 expression in the cytoplasmic fraction
was reduced with overexpression of MOG1 (Fig. 2.9B). These results suggest that
MOG1 increases cell surface expression of Nav1.5, which is consistent with the result
that co-expression of MOG 1 and Nav1.5 increased sodium channel densities (Fig. 2.3
and Fig. 2.6).

2.5 DISCUSSION
Here we report a new interacting protein for the cardiac sodium channel Nav1.5
and its effects on the activity of the cardiac sodium currents. Using a yeast two-hybrid
screen, we identified MOG1 as a candidate protein that interacted with the cytoplasmic
loop II of Nav1.5. In vitro GST pull-down analysis showed interaction of MOG1 with
loop II, but not with the loop I between domains I and II. These results suggest that the
loop II of Nav1.5 is the domain that interacts with MOG1. Both in vitro GST pull-down
and in vivo co-immunoprecipitation analyses further demonstrated this interaction. Overexpression of MOG1 in both HEK293/Nav1.5 cells and neonatal cardiomyocytes resulted
in increased whole-cell sodium current density, whereas knockdown of MOG1
expression dramatically reduced or eliminated sodium currents. Our results reveal a new
role for MOG1 and suggest that this small protein is a critical component in the multiprotein complex of the cardiac sodium channel with a strong modulatory effect on Nav1.5.
Increased sodium current densities in HEK293/Nav1.5 cells caused by the overexpression of MOG1 suggest that there is either an increase in the number of sodium
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channels on the cell surface or an enhancement in single channel conductance. Kinetic
analysis of the steady-state activation and inactivation kinetics of Nav1.5 in
HEK293/Nav1.5 cells over-expressed with MOG1 revealed a small 4 mV hyperpolarizing
shift in activation with little or no effects on channel inactivation. This, by itself, does
not come close to accounting for the increase (~60 pF/pA) in the current density in
HEK293/Nav1.5 cells with overexpression of MOG1. Following examinations of excised
patches from HEK293/Nav1.5 cells over-expressed with MOG1, we further revealed no
effect on single channel conductance (data not shown). These results prompted us to
examine the possibility that an increase in the number of sodium channels on the cell
surface may be the underlying mechanism for the finding of increased sodium current
densities by MOG1. This hypothesis was tested by Western blot analysis, which revealed
an increase of Nav1.5 expression in the plasma membrane (Fig 2.9A), and a decrease of
Nav1.5 expression in the cytoplasm of HEK293/Nav1.5 cells over-expressed with MOG1
(Fig 2.9B). Taken together, the available evidence supports a model in which MOG1
increases the number of sodium channel and/or availability on cell surface, which then
results in an increase in sodium current density.
The exact physiological role of MOG1 was previously unknown.

The only

function of MOG1 reported to date is to form a complex with Ran (Oki et al. 1998). The
hypothesized roles of hMOG1 for facilitating the release of GTP and for promoting
nueclar transport of other proteins remain to be determined. Expression of MOG1 has
been demonstrated in both the nucleus and cytoplasm. One function of cytoplasmic
MOG1 may be to regulate the function of Nav1.5. This hypothesis is further supported
by the finding that MOG1 is highly expressed in intercalated disks of heart as Nav1.5
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does, which suggests that it plays a very important role in the cardiac cells. Northern blot
analysis revealed that the heart was the tissue with the highest expression level of MOG1
(Marfatia KA et al. 2001). In this study, we studied the expression of MOG1 in the
mouse heart at the protein level using two independent antibodies that were specific to
MOG1. Our immunostaining results revealed that the expression of MOG1 protein was
specifically high in both atrial and ventricular tissues compared to the AV node (Fig.
2.8C).

Interestingly, the protein expression of MOG1 was highly localized at the

intercalated discs or the cell-to-cell junctions. The expression pattern of MOG1 was
similar to the pattern shown by connexin 43, the primary gap junctional protein in cardiac
myocytes, whereby the expression was localized to the intercalated discs of both the
atrium and ventricular sections (Fig. 2.8D).

As intercalated discs are essential for

regulating electrical coupling between cells in the myocardium, co-localization of MOG1
and Nav1.5 in these regions suggests that MOG1 may play an important role in
establishing and regulating electrical connections between cardiomyocytes.
MOG1 is highly conserved from yeast to humans, suggesting that it is an essential
protein for cellular functions. However, the specific physiological function(s) of MOG1
is obscure. MOG1 was shown to interact with Ran GTPase, a protein is required for the
trafficking of proteins and RNA in and out of the nucleus, and mediates the release of
GTP from Ran in vitro (Oki et al.1998, Quimby et al. 2003). Thus, MOG1 was proposed
to play a regulatory role in nuclear import and export by maintaining the Ran-GTP
gradient from the nuclei to the cytoplasm (Steggerda et al. 2000).

During the

nucleocytoplasmic transport, MOG1 was proposed to shuttle between the cytoplasm and
the nucleus (Steggerda et al. 2000). Indeed, in HEK293 cells, human MOG1 is localized
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throughout the cell (Marfatia et al. 2001).

Due to its cytoplasmic localization, the

function of MOG1 may not be restricted to the nucleus, on the contrary, it may function
outside of the nucleus. A research group showed that yeast MOG1 may interact with an
osmotic stress sensor Sln1p and regulates the SLN1-SKN7 signal transduction in yeast
(Lu et al. 2004). It is interesting to note that Sln1p is a plasma membrane protein,
specifically a two-transmembrane domain sensor of the high-osmolarity glycerol (HOG)
response pathway (Lu et al. 2003). These results suggest that MOG1 can interact with a
plasma membrane protein. Thus, our finding of the interaction between MOG1 and
membrane protein Nav1.5 is no surprise. Oki and co-workers recently showed that yeast
MOG1 can also interact with Cid13 (a poly(A) polymerase for suc22 mRNA encoding a
subunit of ribonucleotide reductase) with a potential role in regulation of cell cycle S-M
transition (Oki et al. 2007). In addition, genetic suppression studies in yeast implicated
that MOG1 could be required for membrane localization of Opi3p, a phospholipid
methyltransferase required for membrane formation, and might play a role in Ssp1mediated stress response pathway (Oki et al. 2007). To date, all studies that explored the
roles of MOG1 were either in vitro studies or involved yeast. The results from the
present study, for the first time, reveal a novel physiological role for MOG1 in
mammalian cells in vivo and suggest that this small protein is a critical component in the
multi-protein Nav1.5 complex with a modulator role in determining the amplitude of
cardiac sodium currents.

The function(s) of mammalian MOG1 may not overlap

completely with yeast MOG1 as human MOG1 failed to fully replace the yeast MOG1 in
a complementation test of growth defects of a MOG1 deletion yeast strain (Marfatia et al.
2001).
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We found that in cardiomyocytes, MOG1 was mostly localized on cell membrane
and outside of the nucleus (Fig. 2.8E). In HEK293 cells, it was reported that MOG1 was
expressed throughout the cell, including the nucleus and cytoplasm (Marfatia et al. 2001),
however, the study could not distinguish whether MOG1 was also localized on plasma
membrane due to complication of strong signal of MOG1 in cytoplasm. The cell-specific
subcellular localization of MOG1 in cardiomyocytes vs. HEK293 cells is an interesting
observation, but the molecular mechanism warrants further investigations.

Cell- or

tissue-specific proteins that interact with MOG1 may be a rational explanation for the
observation. The interaction with Nav1.5 or other cardiac specific membrane proteins is
expected to recruit MOG1 to the plasma membrane.
In summary, we identified MOG1 as a new interacting protein for Nav1.5. We
further demonstrated that MOG1 modulated the gating kinetics of Nav1.5 and was
required for the function of Nav1.5 channels. This study may have implications in
understanding of the normal physiology of the heart as well as the disease mechanism for
long QT syndrome, Brugada syndrome, cardiac conduction disease, and other diseases
linked to the cardiac sodium channel Nav1.5. Future studies will likely offer more
insights into its role and relevance in myocardial functions.
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CHAPTER III
IDENTIFICATION OF GENES DIFFERENTIALLY EXPRESSED IN
TRANSGENIC MICE WITH CARDIAC EXPRESSION OF LQTS MUTATION
N1325S OF SCN5A BY EXPRESSION PROFILING: INDUCTION OF HIGH
STAT1 EXPRESSION IN TRANSGENIC MICE WITH LQTS AND HEART
FAILURE1

3.1. ABSTRACT
Cardiac-specific expression of the N1325S mutation of SCN5A in transgenic
mouse hearts (TG-NS) resulted in long QT syndrome (LQTS), ventricular arrhythmias
(VT), and heart failure. In this study we carried out oligonucleotide microarray analysis
to identify genes that are differentially expressed in the TG-NS mouse hearts. We
identified 33 genes in five different functional groups that showed differential expression.
None of the 33 genes are ion channel genes. STAT1, which encodes a transcription factor
involved in apoptosis and interferon response, showed the most significant difference of
1

Most of the data in this chapter have been published as Wu L et al. (2007) Biochem Biophys Res Commun
358:449-454. However this chapter has been rewritten for the purpose of this dissertation.
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expression between TG-NS and control mice (a nearly 10-fold increase in expression, P =
4×10−6). The results were further confirmed by quantitative real-time PCR and Western
blot analyses. Accordingly, many interferon response genes also showed differential
expression in TG-NS hearts. This study represents the first microarray analysis for LQTS
and implicates STAT1 in the pathogenesis and progression of LQTS and heart failure.

3.2. INTRODUCTION
The long QT syndrome (LQTS) is characterized by prolongation of the QT
interval and T wave abnormalities on electrocardiograms (ECG) (Curran et al. 1995 and
Wang et al. 1995). LQTS is associated with symptoms including syncope, seizures and
sudden death caused by a specific ventricular arrhythmia, torsade de pointes (Curran et al.
1995 and Wang et al. 1995). One of the major genes identified for LQTS is the SCN5A
gene on chromosome 3p21–23 (LQT3), which accounts for 10–20% LQTS cases (Wang
et al. 1995). SCN5A encodes a voltage-gated sodium channel Nav1.5, which is mainly
expressed in the heart and responsible for the generation and rapid propagation of
electrical signals (action potentials) in cardiomyocytes (Gellens et al. 1992). Besides
gain-of-function mutations associated with LQTS, loss of function mutations in SCN5A
were demonstrated to be involved in the pathogenesis of both Brugada syndrome (Chen
et al. 1998) and progressive cardiac conduction defects (PCCD) (Tan et al. 2001).
Mutations of SCN5A have also been reported to be involved in dilated
cardiomyopathy/heart failure and atrial fibrillation (Olson et al. 2005 and Zicha et al.
2004).
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The N1325S mutation in SCN5A is a substitution of an asparagine residue by a
serine residue at position 1325 in the intracellular region of domain III S4–S5 of Nav1.5,
and is one of the earliest mutations identified in LQT3 families (Wang et al. 1995). It
disrupts the Na+ channel inactivation and generates the late persistent inward current INa.
Overexpression of the N1325S mutation in Xenopus oocytes and HEK293 cells induced
dispersed reopening in the late inactivation phase, which produced a late persistent
inward sodium current (Dumaine et al. 1996 and Wang et al. 1996). We have expressed
the SCN5A N1325S mutation in the mouse heart (TG-NS mice) (Tian et al. 2004). The
TG-NS transgenic mice showed prolongation of the QT interval on ECG and high
incidences of spontaneous polymorphic VT followed by sudden cardiac death (Tian et al.
2004 and Tian et al. 2007). The electrophysiological studies of cardiomyocytes from the
transgenic mice showed that the N1325S mutation produced a late sodium current and
prolonged the cardiac action potential duration, which is expected to prolong the QT
interval on ECG (Tian et al. 2004 and Yong et al. 2007). Recent studies also detected the
phenotype of dilated cardiomyopathy and heart failure in TG-NS mice (Zhang et al. 2006)
as well as in a human patient with the N1325S mutation of SCN5A (Yong et al. 2007).
Age-dependent apoptosis and abnormal calcium handling were also demonstrated in the
TG-NS cardiomyocytes, and are the likely causes of dilated cardiomyopathy and heart
failure (Zhang et al. 2007). However, the molecular mechanism for cardiomyocyte
apoptosis in TG-NS mice is not known. In this study we found that the expression of the
STAT1 gene was highly induced in TG-NS hearts, which may be a cause or mediator of
apoptosis in these mice.
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STAT1 is a member of the Signal Transducers and Activators of Transcription
family of transcription factors which mediate various biological responses, including cell
proliferation, differentiation, survival and apoptosis. The signals are transduced from
various ligands (cytokines, growth factors, stress-induced stimuli) to the nucleus through
Janus tyrosine kinases (JAKs) or mitogen-activated protein (MAP) kinases (Adamkova et
al. 2007).

Seven different STAT family members have been identified, which are

activated by different cytokines (Stephanou et al. 2003). STAT1 has two alternative
RNA splicing isoforms, STAT1α (p91) and STAT1β (p84) (Schindler C et al. 1992).
STAT1β lacks 38 amino acids at the C terminus.

STAT1 forms homodimers or

heterodimers with STAT3, which binds to the interferon-gamma activated sequence
(GAS) on promoters and activates the expression of interferon stimulated genes (ISG).
Upon stimulation by IFN-α or IFN-β, STAT1 forms a heterodimer with STAT2 and binds
to the interferon stimulated response element (ISRE) on promoters (Katze et al. 2002).
STAT1 has been shown to be involved in apoptosis during myocardial ischaemia and
oncogenesis (Stephanou et al. 2000, Adamkova et al. 2007).

STAT1 mediates the

response to interferon (IFN)-α and IFN-γ and has been shown to be pro-apoptotic
(Stephanou et al. 2003). STAT1-deficient mice are more susceptible to development of
tumors, which implicates STAT1 in oncogenesis (Adamkova et al. 2007). No transgenic
mice with over-expression of STAT1 were developed, thus, the physiological effect for
over-expression of STAT1 is unknown.
Microarray analysis is an unbiased approach to study expression of thousands of
genes simultaneously in a system. To date, no microarray analysis or other large-scale
gene expression studies have been performed for LQTS, either in humans or mice. Here,
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we took advantage of our mouse model for LQTS, the TG-NS mice, to explore global
gene expression re-programming in these mice.

We used mouse oligonucleotide

microarrays with 22,690 unique genes to determine gene expression differences between
TG-NS and non-transgenic control mice. A surprisingly large number of genes showed
differential expression between the two types of mice, which may be partly caused by the
marked up-regulation of transcription factor STAT1, as validated by RT-PCR and
Western blot analyses.

These results implicate STAT1 in the pathogenesis and

progression of LQTS and heart failure in this model and may offer insights into the
observation of cardiomyocyte apoptosis in TG-NS mice.

3.3. MATERIALS AND METHODS
Transgenic mice
Human mutant SCN5A gene with the LQTS-causing mutation N1325S was
expressed in the mouse heart using a cardiac specific promoter, the mouse α-myosin
heavy chain (α-mMHC) promoter, and we named this line of transgenic mice as TG-NS.
Transgenic mice with cardiac-specific expression of wild type SCN5A, TG-WT, were
also created. The creation of TG-NS and TG-WT mice was reported by us previously
(Tian et al. 2004 and Zhang et al. 2007), and they carry the comparable number of the
transgenes and have a comparable level of SCN5A expression.

Genotyping of the

positive TG-NS mice was performed by polymerase chain reactions (PCR) using
genomic DNA isolated from mouse tails/toes using the tail lysis buffer (50 mM Tris–HCl,
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100 mM EDTA, 100 mM NaCl, 1% SDS). We used PCR primers 5′-TGT CCG GCG
CTG TCC CTG CTG-3′ and 5′-CTC ATG CCC TCA AAT CGT GAC AGA-3′ for
specific amplification of the SCN5A transgene and primers 5′-GGC ACC TGC TGC
AAC GCT CTT T-3′ and 5′-GGT GGG CAC TGG AGT GGC AAC TT-3′ for
amplification of AGGF1 that serves as an internal control for quality of mouse genomic
DNA. PCR was performed using standard procedures.
Microarray analysis
Total RNA was prepared from heart tissues of the non-transgenic control and TGNS mice. First, heart tissues were homogenized by a polytron homogenizer (PT3100,
Dispersing and Mixing Technology by Kinematica). Total RNA was then isolated using
the TRIzol reagent (Invitrogen). The integrity and purity of the RNA was confirmed
visually on a 1% denaturing agarose gel, and by measuring the optical density ratio
(A260/A280). Double-stranded complementary DNA (ds-cDNA) was synthesized from
15 µg of total RNA using the Superscript Choice System (Invitrogen) with an HPLCpurified oligo-dT primer containing a T7 RNA polymerase promoter (GENSET, La Jolla,
CA) as instructed by the manufacturer. The cDNA was extracted by the Phase Lock Gel
(PLG) kit (Eppendorf) and purified by ethanol precipitation. In vitro transcription was
performed with 1 µg of ds-cDNA using the ENZO BioArray RNA Transcript Labeling
kit (ENZO Diagnostics). Fragmentation of biotinylated cRNA (20 µg), hybridization,
washing, and staining were performed following the instructions by Affymetrix by the
CWRU Gene Expression Core Facility.

The Mouse Genome MOE430A arrays

(Affymetrix) were used. Each array contains about 22,690 genes.
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Statistical analysis
Microarray data was extracted from scanned images.

GeneSpring 7.0

(Silicogenetics) was used to compare the data from three transgenic mice (6–8 months of
age, male) with those from three non-transgenic control littermates. All samples were
considered as one group of replicates. The algorithm to generate a list of genes that
showed a statistically significant difference between the two groups was described
previously (Archacki et al. 2003 and Tan FL et al. 2002). The median value for group
comparisons was used. All raw data with a score less than zero were set to zero. Genes
were further filtered by an absolute call: present (P) or marginally present (M) in the two
groups for the up-regulated genes and down-regulated genes.
Quantitative real-time PCR (RT-PCR)
Quantitative RT-PCR was performed using an ABI Prism 7900HT Sequence
Detection System (Applied Biosystems). Total RNA was extracted from hearts using
TRIzol (Invitrogen). Reverse transcription was performed with 5 µg of RNA using the
Superscript Choice System (Invitrogen). Primers spanning exon-intron junctions were
designed to avoid amplification of genomic DNA. PCR conditions were 50°C for 2 min
and 95°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C for 1 min.
Fluorescence changes were monitored with SYBR Green PCR Supermix (VWR) after
every cycle, and melting curve analysis was performed at the end of 40 cycles to verify
PCR product (0.5°C/s increase from 55–99°C with continuous fluorescence reading). The
18S gene was used to normalize samples for comparison. To quantify changes in gene
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expression, the ∆∆Ct method was used to calculate the relative fold changes as previously
described (Livak et al. 2001).
Western blot analysis
To determine the expression level of the STAT1 protein, total proteins were
extracted from hearts of transgenic and normal mice. Hearts from 7-8 months old mice
were homogenized with Polytron, and lysed on ice with the lysis buffer (0.5% NP-40, 20
mM Tris–HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA and proteinase inhibitor cocktail).
The protein concentration was measured using the Bradford method (Bio-Rad). Western
blot analysis was then performed.

Briefly, equal amounts of protein extracts were

separated on 10% SDS–polyacrylamide gels by electrophoresis.

The blots were

incubated with agitation at room temperature in the presence of a rabbit polyclonal anti–
STAT1 antibody (Santa Cruz Biotechnology) (diluted in 1:500 in 0.3% BSA in PBST).
The signal was detected using enhanced chemiluminescence (ECL kit, Amersham
Biosciences). An anti-β-actin antibody and an anti-GAPDH antibody (Sigma–Aldrich)
were used as loading controls at 1:1,000 dilution in PBST.

3.4. RESULTS
Identification of genes differentially expressed in the hearts from TG-NS mice
We investigated the gene expression profiles from three TG-NS mice and three
age- and sex-matched control mice using the Affymetrix Mouse Genome MOE430A
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Arrays. 2492 of 22,690 genes showed significant expression differences between the two
groups if P 0.05 (Welch t-test). Because of the large number of genes identified, filters
exceeding 2- and 5-fold changes and several different P values were applied. The results
are summarized in Table 3.1. With P 10−5, only two genes, STAT1 encoding signal
transduction and activator of transcription factor 1 and DLM-1 encoding Z-DNA binding
protein 1, showed an expression difference between two groups of mice. At P value of
10−4, 11 genes showed differential expression of

5-fold, 9 up-regulated and 2 down-

regulated (9↑, 2↓). At P value of 10−3, 33 genes (31↑, 2↓) showed expression differences
of

5-fold. The number of genes increased to 14 at P 10−4 and 65 at P 10−3 if the cut

off expression difference was set to 2-fold (Table 3.1).
Our further analysis was focused on genes showing a large differential expression
difference, i.e. those showing 5-fold expression differences and P value of

0.001. As a

result, 31 genes were found to be up-regulated and 2 genes down-regulated in TG-NS
mice (Table 3.1). These genes can be divided into five functional groups: 11 genes are
involved in interferon-responses; 4 genes are related to apoptosis and inflammation; 4
genes may mediate other immune responses; 4 genes encode enzymes; 11 unknown
genes (Table 3.2 and Supplementary Table 3.1).
Validation of microarray results by real-time PCR (RT-PCR)
To verify the results from the microarray analysis, quantitative RT-PCR was
performed with 9 additional TG-NS and 7 control mice (6–8 months of age). Results
from RT-PCR analysis of 6 highly significant genes, including STAT1, Usp18, Oas1 1G,
Helicard, Trim34 delta, and Phgdh, are shown in Table 3.3. The real-time PCR results
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Table 3.1. Summary data for the number of genes showing differential expression in
TG-NS hearts

Fold difference of

P value

expression
0.01

0.001

0.0001

0.00001

2-fold

470

54

12

2

5-fold

101

31

9

2

2-fold

306

11

2

0

5-fold

53

2

2

0

Up-regulated genes

Down-regulated genes
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Table 3.2 List of genes showing differential expression in TG-NS hearts by
microarray analysis1
Accession #

Symbol Gene

P value

Fold of
change

1.3 x 10-4

43.9

6.5 x 10-5
8.3 x 10-4

31.8
31.5

2.2 x 10-4

26.0

1.3 x 10-4
1.8 x 10-4

18.6
13.5

8.6 x 10-6

12.9

(A) Genes involved in interferon (IFN)-signaling pathways
NM_008332.1

Ifit 2

NM_011909.1
NM_010501.1

Usp18
Ifit 3

NM_008331.1

Ifit 1

NM_016850.1
NM_018734.1

Irf 7
Gbp3

AF136520

Dlm-1

NM_009283

STAT1

AB067533.1
BC018470

Oasl 9
Oasl

2

Interferon-induced protein with
tetratricopeptide repeats 2
Ubiquitin specific protease 18
Interferon-induced protein with
tetratricopeptide repeats 3
Interferon-induced protein with
tetratricopeptide repeats 1
Interferon regulatory factor 7
Guanylate nucleotide binding protein
3
Tumor
stroma
and
activated
macrophage protein DLM-1
Signal transducer and activator of
transcription 1
2,5-Oligoadenylate synthetase-like 9
2'-5' Oligoadenylate synthetase 1G

4.0 x 10-6

9.8

9.8 x 10-4
2.0 x 10-4

6.6
6.5

1G
AY090098.1

Isg 12

Interferon stimulated gene 12

2.7 x 10-4

6.2

NM_009283

STAT1

4.0 x 10-6

9.8

AY075132

Helicar
d
Trim34
delta
Tlr3

Signal transducer and activator of
transcription 1
Helicard

2.1 x 10-5

7.9

Tripartite motif protein 34 delta

8.1 x 10-5

5.5

Toll-like receptor 3

2.5 x 10-4

5.4

AF220142
NM_126166

2

(B) Genes with a potential role in apoptosis and inflammation
2.1 x 10-5
7.9
Helicar Helicard
d
5.5
AF220142
8.1 x 10-5
Trim34 Tripartite motif protein 34 delta
delta
NM_126166
Toll-like receptor 3
2.5 x 10-4
5.4
Tlr3
1
Additional genes showing differential expression in TG-NS hearts are listed in Appendix
C. 2STAT1 is involved in both IFN signaling and apoptosis.
AY075132
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Table 3.3 Conformation of results from mircroarray analysis by RT-PCR
Microarray1

Gene

RT-PCR2

STAT1:Signal transducer and activator of transcription 1 9.8

8.4

Usp18: Ubiquitin specific protease 18

31.8

65.9

Oas1 1G: 2'-5' Oligoadenylate synthetase 1G

6.5

14.9

Helicard: Helicard

7.9

3.4

Trim34 delta: Tripartite motif protein Trim34 delta

5.5

7.9

Phgdh: 3-Phosphoglycerate dehydrogenase

53.8

66.3

1

data of fold difference of expression between 3 TG-NS and 3 control mice. 2data of fold
difference of expression between 9 TG-NS and 7 control mice; no overlapping of
samples between the microarray and RT-PCR studies.
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generally confirmed the results from microarray analysis.

Liner regression analysis

demonstrated a strong positive correlation between the two technological platforms with
R=0.93.
STAT1 showed the most significant differential expression in TG-NS mice
STAT1 is the gene showing the most significant expression difference between TGNS and control mice with a P value of 4.0 × 10−6 and a fold difference of 9.8 (Table 3.2).
In addition to the RT-PCR analysis described above (Fig. 3.1A and Table 3.3), Western
blot analysis was also used to validate the finding of increased STAT1 expression in TGNS mice compared to control littermate mice (Fig. 3.1B).

Western blot analysis

demonstrated that the basal expression level of the STAT1 protein in non-transgenic
control mice was low, however, it dramatically increased in TG-NS hearts (Fig. 3.1B).
Recently, we created and studied transgenic mice with cardiac-specific expression
of wild type SCN5A (TG-WT) (in contrast to TG-NS with mutant SCN5A containing the
N1325S mutation) (Zhang T et al. 2007). TG-WT mice did not develop LQTS, VT, or
heart failure (Zhang T et al. 2007), thus they could serve as an excellent control for TGNS mice (note that the TG-WT mice were not available when the microarray project
started). Western blot analysis was used to compare the expression level of the STAT1
protein between TG-NS to TG-WT mice. As shown in Fig. 3.1C, the expression level of
STAT1 in TG-WT heart was comparable to that in non-transgenic control hearts, but
much lower than that in TG-NS hearts. These results suggest that induction of STAT1
expression is specific to TG-NS mice with the SCN5A mutation N1325S.
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Fig. 3.1. Markedly increased expression of STAT1 in TG-NS hearts. (A) Quantitative
RT-PCR analysis with RNA isolated from 9 TG-NS and 7 NTG (non transgenic control)
hearts (age = 6–8 months). Data were normalized to 18S RNA expression in the same
samples and reported as fold changes (mean ± SE) from levels in control mice
(*P = 0.0016). (B) Western blot analysis of STAT1 from three NTG and three TG-NS
hearts (age = 6–8 months). β-Actin was used as loading control. The experiment was
repeated three times and similar results were obtained. (C) Western blot analysis of
STAT1 from non-transgenic control (NTG), TG-NS, and TG-WT hearts (age = 6–8
months). The experiment was repeated twice and similar results were obtained. Note that
TG-NS and TG-WT have the comparable copy number of the transgene and a similar
level of expression of the cardiac sodium channel (see Reference by Zhang T et al. 2007).
The only difference between these two types of mice is that TG-NS mice carry the
mutant N1325S SCN5A and TG-WT mice carry the wild type SCN5A.
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3.5. DISCUSSION
Microarray analysis is a large scale study that can provide unbiased assessment of
expression of thousands of genes in a cell or tissue simultaneously.

To date, no

microarray analysis has been reported for LQTS either in the humans or mice. We
performed a microarray study using a mouse model for LQTS, the TG-NS mice with
cardiac expression of the SCN5A mutation N1325S associated with LQTS. Microarray
analysis revealed 33 genes showing marked differential expression between TG-NS and
wild type mice (>5-fold difference, P 0.001). The results from microarray analysis
were almost identical to that from the follow-up RT-PCR analysis using independent
samples for all selected genes.

Our results suggest the involvement of expression

remodeling in the progression of LQTS. Furthermore, the results from this study suggest
that in addition to its effects on basic biophysical properties of the cardiac sodium
channel, the N1325S mutation has a more profound effect on cardiomyocytes in vivo.
The gene that showed the most significant difference between TG-NS and wild
type mice is STAT1. Follow-up RT-PCR and Western blot analysis confirmed that
expression of STAT1 was markedly increased in TG-NS myocytes compared to nontransgenic control cells. Further analysis showed that STAT1 protein expression was
also much higher in TG-NS hearts than in TG-WT hearts with cardiac expression of wild
type SCN5A (Fig. 3.1C). STAT1 is a key signaling protein that functions as a transducer
of cytokine signaling and as a sensor responding to cellular stresses, in particular, IFN
response (Stephanou et al. 2003). Thus, it was interesting to note that many genes
involved in the IFN response also showed increased expression in TG-NS myocytes, for
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example, Usp18, Ifit1, Ifit2, Ifit3, Irf7, Gbp3, Dlm-1, Oasl 9, Oasl 1G, and Isg 12 that all
showed many fold increases of expression (Table 3.2). The molecular mechanism for
induction of high STAT1 expression in TG-NS hearts is not clear, however, abnormal
handling of intracellular calcium transients detected in TG-NS cardiomyocytes (Yong SL
et al. 2007) may be a likely cause.
STAT-1 has been shown to induce apoptosis. Human fibroblast cells deficient in
STAT1 were resistant to TNF-α-induced apoptosis (Kumar et al.1997). Neonatal rat
cardiomyocytes subjected to ischemia for 4 h showed increased expression of STAT1, and
cardiomyocytes transfected with STAT1 showed increased apoptosis with exposure to
ischemia (Stephanou et al. 2000). A trend of increased apoptosis in the absence of
exposure to ischemia was also detected in cardiomyocytes transfected with a STAT1
construct compared to control cells transfected with the vector (Fig. 3A in Stephanou et
al. 2000). Because age-dependent apoptosis has been detected in TG-NS mouse hearts
(Zhang T et al. 2006), we speculate that increased expression of STAT1 may be a cause
for apoptosis in these mice.
In summary, our microarray analysis of a transgenic mouse model for LQTS, TGNS, demonstrated that gene expression remodeling existed in these mice. Of a particular
interest was the finding of highly increased STAT1 expression, which may provide
insights into the findings of cardiomyocyte apoptosis in TG-NS mice and high risk of
heart failure in these mice.
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CHAPTER IV

INVESTIGATION OF LOCALIZATION OF NAV1.5 IN NON-CARDIAC
TISSUES: EVIDENCE OF Nav1.5 IN THE MOUSE BRAIN1

4.1 ABSTRACT

SCN5A encodes a sodium channel α-subunit Nav1.5 that is predominantly
expressed in the heart. Mutations in the human Nav1.5 gene cause long QT syndrome
and Brugada syndrome that are characterized by cardiac arrhythmias and sudden death
during sleep or at rest. SCN5A mRNA was recently shown to be present in the rat and
human brain. In this report, we determined the distribution of Nav1.5 protein in the
mouse brain. We generated a polyclonal antibody specific to Nav1.5. The anti- Nav1.5
antibody was used for immunohistochemical analysis of the Nav1.5 distribution. We
found that Nav1.5 protein was present widely throughout the brain, and was found in the
cerebral cortex, limbic system, basal ganglion, thalamus, hypothalamus, cerebellum, and
brainstem. The distribution of Nav1.5 immunoreactivity appeared to be more widespread
1

Most of the data in this chapter have been published as Wu l et al. (2002) Neuroreport 13:2547-2551.
However this chapter has been rewritten for the purpose of this dissertation.
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than previously reported for the mRNA. Notably, Nav1.5 protein was clustered at a high
density in neuronal processes and nerve fiber bundles, but not in cell bodies. Further
confocal microscopic analysis revealed that Nav1.5 protein was localized on the surface
membrane of the neuronal processes in the brain, and surrounded the neurofilaments.
The wide distribution of Nav1.5 protein in the brain and its distinct localization to the
membrane of neuronal processes suggest that this protein may play a role in the
physiology of the central nervous system. Abnormal neuronal activity associated with
Nav1.5 mutations might affect the coordination of cardiac rhythm by an indirect
mechanism, which may trigger seizures, syncope, life-threatening arrhythmias, or sudden
death in arrhythmic and epileptic patients.

4.2. INTRODUCTION
Voltage-dependent sodium channels are transmembrane proteins that are
responsible for generating action potentials and for rapid conduction of electrical signals
in excitable cells (Catterall et al. 2000). Sodium channels are classified into three types
based on their sensitivity to blockade by tetrodotoxin (TTX): TTX-sensitive Na channels
(TTXs), TTX-resistant Na channels (TTXr), and TTX-insensitive Na channels (TTXi)
(Donahue et al. 2000, Fozzard et al. 1996). In the brain, six TTXs Na channels have been
identified, including Nav1.1, Nav1.2, Nav1.3, Nav1.6, Nav1.7. Only one TTXr channel,
Nav1.9, has been identified in the brain (Jeong et al. 2000). Recent studies suggested that
SCN5A may be another gene that is responsible for generating TTXr Na currents in the
brain (Donahue et al. 2000; Hartmann et al. 1999). TTXr Na channels generate currents
that are slower, but recover from inactivation much faster than TTXs channels (Elliott et
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al. 1993), suggesting a possible role of TTXr sodium channels in sustained firing of
neurons or as pace-makers. In this study, we investigated the localization pattern of
another TTXr sodium channel, Nav1.5, in the mouse brain using immunohistochemistry.
SCN5A encodes the cardiac sodium channel with 2,016 amino acids and a
calculated molecular weight of 227 kDa (Gellens et al. 1992). The putative structure of
Nav1.5 consists of four homologous domains (I-IV), each containing six transmembrane
segments (S1-S6). Nav1.5 mutations cause syncope, seizures, and sudden death triggered
by lethal cardiac arrhythmias associated with long QT syndrome (LQTS), idiopathic
ventricular fibrillation including Brugada syndrome and cardiac conduction disease
(Wang et al. 1995a; Chen et al. 1998). Nav1.5 was originally identified as a cardiac
sodium channel. Subsequently, it was shown to be expressed in the brain at the mRNA
level (Donahue et al. 2000; Hartmann et al. 1999).

In situ hybridization, reverse

transcription polymerase chain reaction (RT-PCR), and RNase protection assays detected
the presence of transcripts of SCN5A in the human and rat brain tissues. Restricted
regional expression of SCN5A mRNA involved piriform cortex and subcortical limbic
nuclei (Donahue et al. 2000; Hartmann et al. 1999), and these two regions are related to
epilepsy. These findings may explain why Nav1.5 mutations are associated with seizures.
However, the distribution of Nav1.5 in the brain at the protein level has not been
investigated previously. Here, we demonstrate selective expression of Nav1.5 at the
protein level in regions of the mouse central nervous system.
In this study, we investigated the localization pattern of Nav1.5 protein in the
mouse brain tissues using immunohistochemistry. We generated an antibody directed
against a unique peptide region at the N-terminus of Nav1.5. The antibody was used to
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define the distribution of Nav1.5 in mouse brain. We demonstrated that Nav1.5 protein
was widely localized in the cerebral cortex, thalamus, hypothalamus, basal ganglia,
cerebellum and brainstem. Our studies confirmed the distribution of Nav1.5 protein in
some regions that were previously shown to contain the corresponding mRNA, but also
revealed the presence of Nav1.5 protein in new brain regions where Nav1.5 gene
expression has not been previously reported. Our data also indicate that Nav1.5 protein is
expressed and localized on the plasma membrane of the neuronal processes, but not in the
cell bodies. The regional distribution of Nav1.5 in the brain suggests that Nav1.5 might
regulate neuron excitability.

4.3 MATERIALS AND METHODS
Materials
An Nav1.5-specific polyclonal antibody was developed against a synthetic
polypeptide (AC-RPQLDLQASKKLPDLYC-Amide) corresponding to a unique portion
of the N-terminus of the cardiac sodium channel Nav1.5. The antibody was generated
and purified as described (Harlow et al. 1988).
The mouse anti-neurofilament 200 antibody (clone NE14) was purchased from
Sigma (St Louis, MO) and used at 1:40 dilution for immunohistochemistry. Fluoresceinconjugated secondary antibodies were from Jackson Immuno Research Laboratories
(West Grove, PA), and used at 1:200 dilution. The Vectastain elite ABC kit, DAB
substrate kit, and Vectashield anti-fading mounting media were from Vector Laboratories
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(Burlingame, CA). The brain tissues for Western blotting and immunohistochemical
analyses were from the mouse strain c57BL.

Western blot analysis
Mouse tissues from the heart, brain, kidney, liver, and skeletal muscle were
homogenized with a glass tissue grinder (Wheaton, Millville, NJ) in 1X PBS buffer
containing 0.1% NP-40, 0.05% sodium deoxycholate, and a protease inhibitor cocktail
mix (Roche Biochemicals, Germany). The sample was centrifuged at 3,000 rpm for 10
minutes, and the supernatant was transferred to a microcentrifuge tube. The supernatant
was then undergone ultracentrifugation at 40,000 rpm for 30 minutes.

The pellet

containing the membrane fraction of proteins was resuspended in the loading buffer
containing 2% SDS, and denatured at room temperature for 30 minutes before loading
onto SDS-PAGE. Western blot analysis was performed as described (Harlow et. al. 1988)
with the anti- Nav1.5 antiserum as the primary antibody. The secondary antibody was
horseradish peroxidase-conjugated donkey anti-rabbit IgG (NA 934, Amersham
Pharmacia Biotech, Inc., Piscataway, NJ). ECL Western blotting detection reagents
(Amersham Pharmacia Biotech, Inc., Piscataway, NJ) were used to visualize the protein
signals.
For HEK293 cells with or without expression of Nav1.5, cells were lysed in the
lysis buffer (1% Triton-100, 150 mM NaCl, 50 mM Tris-HCl, pH7.5, 1 mM EDTA) with
a protease inhibitor cocktail mix on ice for 30 min. The sample was then centrifuged at
14,000 rpm for 25 min at 40C. The supernatant was used for Western blot analysis as
described above.
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Immunohistochemistry
Immunostaining was carried out as previously described (Nishiyama, et al. 1997)
with minor modifications.

Briefly, mouse brain sections fixed with 4%

paraformaldehyde and embedded with paraffin or frozen sections were pretreated with
hydrogen peroxide, blocked in blocking buffer (5% bovine serum albumin and 0.3%
Triton X-100 in 1x PBS) for 2 hr, and then incubated with the primary antibody (1:250
dilution) at 4°C for 24 hours.

The sections were then incubated with the biotin-

conjugated secondary antibody and the avidin-biotin complex solution (Vectastain Elite
ABC Kit). Immunoreactive signal was developed using the DAB substrate kit (Vector
Laboratories, Burlingame, CA).
In control experiments, serial brain sections were stained with the primary antiNav1.5 antibody preincubated with an excessive amount of the immunizing peptide
antigen (100 µg of peptide vs. 13.7 µg of the anti- Nav1.5 antibody).
Double immunofluorescence staining was carried out using the protocol similar to
those reported previously (Nishiyama et al. 1999). In brief, mouse brain sections of 12
µm thickness were prepared from paraffin-embedded or frozen tissues, blocked, and
incubated with the mixture of primary antibodies (the anti-Nav1.5 antibody and the
monoclonal anti-neurofilament 200 antibody) at 4°C for 24 hours. The sections were
then incubated with a secondary antibody mixture containing the FITC-conjugated and
Texas Red-conjugated secondary antibodies at room temperature for 2 hours.

The

immunostained slides were mounted with anti-fading media, and visualized under a
confocal microscope.
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Confocal microscope and image processing
Tissue sections immunostained with DAB were analyzed with transmitted light or
Nomarski optics using a Zeiss Axiophot photomicroscope.

Images observed were

digitized using a Hamamatsu CCD camera, and transferred to a Power Macintosh G4
computer for digital image processing. Digital images were processed using software
Adobe PhotoShop 5.5.
For immunocytochemical analysis, a confocal laser-scanning microscope (SP2;
Leica, Heidelberg, Germany) equipped with 40x, 63x and 100x infinity-adjusted oil
immersion objectives and double-channel photodetectors was used.

By precisely

stepping the microscope stage in the vertical z-axis, a series of optically thin, perfectly
focused images were collected at identical x-y planes through the specimen. In general,
each data set collected on the confocal microscope was processed with the 3D software of
the Leica Scan Ware operating system, and used to construct an extended focus image,
i.e., a computer-averaged assembly of some or all optical sections in the data set. These
procedures resulted in a perfectly focused image through the depth of the specimen which
was then saved in a TIFF file format and transferred to a Power Macintosh G4 for image
processing. Digital images were colorized, and then combined and manipulated using
Adobe PhotoShop 5.5.

Over-expression of NaV1.5 in HEK293 and P19CL6 cells
Wild type Nav1.5 cDNA was cloned into the pcDNA3 vector (Invitrogen,
Carlsbad, CA) for expression in HEK293 and P19C16 cells (Wan et al. 2000; Wan et al.
2001). Approximately 1 x 105 P19CL6 cells were seeded on chamber coverglass (Nalge
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Nunc International, Naperville, IL) a day prior to transfection.

Two microliters of

Lipofectamine (Invitrogene, Carlsbad, CA) was diluted in 50 µl of the serum free
medium, and mixed with one microgram of Nav1.5 expression plasmid DNA in 50 µl of
the serum free medium. After incubation at room temperature for 20 minutes, the DNALipofectamine complexes formed and were added into chamber slide wells. The serum
free medium was replaced with the growth medium after 4-6 hours. After 48 hours of
incubation, the cells were ready for immunostaining. The cells were fixed with 4%
paraformaldehyde, blocked in the blocking buffer (5% bovine serum albumin and 0.3%
Triton X-100 in 1x PBS), and incubated with the primary anti-Nav1.5 antibody. The
secondary antibody used was FITC-conjugated anti-rabbit IgG.

The images were

visualized with a confocal microscope as described above.

4.4. RESULTS

Characterization of the anti- Nav1.5 polyclonal antibody
A polyclonal antibody specific to the Nav1.5 channel was generated using a
peptide immunogen located at the cytoplasmic N-terminus of Nav1.5 protein (amino
acids 53 to 68: RPQLDLQASKKLPDLY). To confirm the specificity of the anti- Nav1.5
antibody, we performed Western blot analysis on the membrane fractions of protein
extracts from a number of mouse organs, including heart, kidney, liver, brain, skeletal
muscle, and human embryonic kidney cells (HEK293) expressing human Nav1.5. The
antibody detected a band approximately the expected size of 227 kDa (Wang et al. 1996)
strongly in the heart, and very weakly in the brain, but not in the kidney, liver, and

92

skeletal muscle (Fig. 4.1A). These data are consistent with the results from Northern blot
analysis (Gellens et al. 1992). The antibody also yielded the expected 227 kDa band in
the lane loaded with protein extract from the transfected cells containing Nav1.5 (Fig.
4.1B). No equivalent band was detected in the control non-transfected cells (Fig. 4.1B).
These data suggest that our antibody is specific for Nav1.5.
To further establish the specificity of this antibody, we determined whether the
antibody binds to the cell membrane where Nav1.5 is known to be localized.
Immunofluorescence staining with HEK293 and P19C16 cells transfected with the
Nav1.5 expression construct DNA detected Nav1.5-imunoreactivity only on the plasma
membrane (Fig. 4.1C). No localization was evident when the antibody was pre-absorbed
with an excessive amount of the peptide to which the antibody was prepared (Fig. 4.1C).
Together, these data suggest that our anti- Nav1.5 antibody specifically recognizes
Nav1.5 protein and that the wild type Nav1.5 protein is localized to the plasma membrane
when expressed in non-neuronal cultured cells.

Regional distribution of Nav1.5 protein in the brain
Immunohistochemistry using this anti-Nav1.5 antibody was performed to
determine the distribution of Nav1.5 immunoreactivity in the normal mouse brain. Unlike
the Nav1.5 mRNA, which was reported to be expressed primarily in the limbic system
(Donahue et al. 2000; Hartmann et al. 1999), the Nav1.5 protein seemed to be more
broadly expressed in various brain regions with some unique features (Fig. 4.2). In the
immunohistochemistry experiments, a negative control was carried out on the adjacent
brain sections with the anti-Nav1.5 antibody pre-absorbed with the antigen peptide.
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Fig. 4.1. Characterization of the anti-Nav1.5 antibody. (a) Western blot analysis of
mouse membrane proteins from the heart, kidney, liver, brain, and skeletal muscle tissues
with the anti-Nav1.5 antibody. The positions of molecular weight markers are indicated.
(b) Western blot analysis with protein extracts from HEK293 cells expressing Nav1.5
(transfected cell), and control cells that were not transfected with the Nav1.5 expression
construct (non-transfected cell). (c) Cellular localization of wild type human SCN5A
protein on plasma membrane (green signal). HEK293 cells (left) and P19CL6 cells
(middle) transfected with the human SCN5A expression construct were immunostained
with the anti-SCN5A antibody. No detectable immunofluorescence staining was observed
with the anti-SCN5A antibody pre-absorbed with the peptide antigen (right). Bar = 5 µm.
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Elimination of Nav1.5 immunoreactivity in the negative control experiments (compare
Figs. 4.2A and 4.2B), as expected, demonstrated that positive Nav1.5 staining or the
Nav1.5 -immunoreactivity represented the specific binding of our antibody to the
immunogenic peptide sequence of Nav1.5.
In the forebrain of the adult mouse, a weak, but significant, Nav1.5
immunoreactivity was observed in the cerebral cortex (Fig. 4.2C). Within this region, the
neuronal processes originating from cerebral cortical neurons were positively stained for
Nav1.5, whereas little or no immunoreactivity was detected in the neuronal cell bodies or
glial components in this region (Fig. 4.2C). In contrast, none of the neurons in the
dentate gyrus and hippocampus were positively stained for Nav1.5, and even the neuronal
processes showed little Nav1.5 immunoreactivity in this area (data not shown).
Interestingly, in the forebrain slides we observed intense Nav1.5 signals in the olfactory
tract (Fig. 4.2D), and weak staining in the olfactory tubercule (data not shown).
In the limbic system, little or no immunoreactivity for Nav1.5 was detected in the
cell bodies in the septal nuclei, the diagonal band of Broca, the piriform cortex, and the
amygdala, where Nav1.5 mRNA was reported to be expressed strongly (Donahue et al.
2000; Hartmann et al. 1999). However, moderate Nav1.5 signals were detected in the
nerve fibers within this region (Fig. 4.2A). The discrepancy between Nav1.5 mRNA
localization and Nav1.5 protein distribution may be explained by our hypothesis that
Nav1.5 protein is transported to the nerve fibers after synthesis in the cell bodies of
neurons in the limbic system.
In the basal ganglion, the anti- Nav1.5 antibody showed strong positive staining in
the nerve bundles, also known as the pencil fibers, whereas the cell bodies in the striatal
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Fig. 4.2. Regional distribution of Nav1.5 protein in the mouse brain. (a) Some nerve
fibers in the limbic system express Nav1.5 protein, whereas neuronal and glial cell bodies
were not stained by the anti-Nav1.5 antibody. (b) An adjacent section to the section used
in (a) was stained with the anti-Nav1.5 antibody pre-absorbed with the immunogenic
peptide. (c) In the cerebral cortex, the neuronal processes, mainly axons, were positive
for Nav1.5 protein, but little or no signal was observed in the cell bodies. (d) The
olfactory tract had strong Nav1.5 signal. (e) In the striatum, Nav1.5 protein was mainly
localized to the nerve fibers (the pencil fibers). (f) The cerebral peduncle was stained by
the anti- Nav1.5 antibody. (g) In the brain stem, some nerve fibers in the lateral medulla
were moderately positive for Nav1.5. (h) In the cerebellum, the white matter consisting of
nerve fibers was strongly stained for Nav1.5, but there was no signal in the granular layer
and the Purkinje cell layer. Bars = 100 µm.
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nuclei showed little or no signal (Figs. 4.2E, 4.3A-4.3C).

Interestingly, Nav1.5-

immunoreactivity in the pencil fibers was significantly stronger within the caudate
putamen (Fig. 4.2E, right half) than within the globus pallidus (Fig. 4.2E, left half). It is
important to note that not all the nerve tracts or nerve bundles through the mouse brain
were positively stained for Nav1.5 immunoreactivity, for example, a huge nerve tract
connecting both hemispheres in the corpus callosum was not positively stained for Nav1.5
(data not shown). These data suggest that the distribution of Nav1.5 protein is restricted
to specific nerve tracts.
In the diencephalon of the adult mouse brain, Nav1.5 immunoreactivity was also
localized to the nerve fiber tracts, and little or no Nav1.5 signal was present in the cell
bodies in the cerebral cortex. The cerebral peduncle was intensively stained for Nav1.5
(Fig. 4.2F). A low level of Nav1.5 immunoreactivity was localized to the hypothalamic
and thalamic nuclei, but the nerve fibers in the hypothalamic and thalamic regions
showed more intense Nav1.5 signal than the cell bodies (data not shown).
In the brainstem, intense Nav1.5 immunoreacitivy was localized to some spotty
regions in the lateral medulla (Fig. 4.2G). These signals seemed to correspond to discrete
nerve tracts in the medulla. Based on a report showing that Nav1.5 mRNA expression is
located in the lateral paragigantocellular nuclei (LPGi) (Donahue et al. 2000), some of
the nerve tracts with Nav1.5 immunoreactivity shown in this study may originate from
LPGi.
In the cerebellum, no negligible signal was detected in the granular layer and the
Purkinje cell layer. However, weak Nav1.5 immunoreactivity on some fibrous structures
was observed in the cerebellar molecular layer, and intense Nav1.5 signals were
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Fig. 4.3. Co-localization of Nav1.5 and neurofilaments. Confocal microscopic images
of caudate putamen immunostained with both the anti-Nav1.5 antibody and the
monoclonal anti-neurofilament 200 antibody. (a) immuno£uorescent image for Nav1.5
protein, green; (b) immunofluorescent image for neurofilaments, red; (c) overlay of
image A and image B. Bar = 200 µ m.
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in the white matter of the cerebellum (Fig. 4.2H). Nav1.5 immunoreactivity was found
mostly in process-like structures, presumably neuronal processes. Neuronal cell bodies
and glial cells did not label with the Nav1.5 antibody.
In conclusion, Nav1.5 protein is widely distributed throughout the central nervous
system, and it is clustered much more densely in the neuronal processes than in the
neuronal cell bodies.
Confocal microscopic analysis to define the subcellular localization of Nav1.5 protein
In the central nervous system, the neuronal processes showed strong Nav1.5immunoreactivity, whereas the cell bodies showed no or very weak signal (Fig.4.2C). To
further characterize the localization of Nav1.5 at the subcellular level, we performed
double-immunostaining with mouse brain sections using both the rabbit anti-Nav1.5
antibody described above and the anti-neurofilament antibody. Fig. 3 shows confocal
microscopic images of the caudate putamen of the basal ganglion. Nav1.5 is clearly
expressed in the nerve tracts identified by the anti-neurofilament antibody (Fig. 4.3A-C).
A highly magnified image of the nerve fibers in this area showed that Nav1.5
immunoreactivity (green) did not overlap with the neurofilament signals (red) (Fig. 4.3DF). The Nav1.5 signals appeared outside the neurofilament compartment, consistent with
the localization of Nav1.5 protein on the neuronal plasma membrane (Fig. 4.3F). These
data suggest that Nav1.5 protein is localized to the plasma membrane of the nerve
processes and is not present in the interior.
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4.5. DISCUSSION
In this report, we describe the immunohistochemical characterization of the
regional and cellular distribution of the cardiac voltage-dependent sodium channel αsubunit (Nav1.5) protein in the mouse brain. We found that the cell bodies of neurons did
not contain Nav1.5. Instead, we observed the striking and distinct subcellular localization
of the Nav1.5 channels on the plasma membrane of neuronal processes (Fig. 4.3) that are
specialized for conducting electrical signals. This distribution is consistent with the
functional role of sodium channels which are responsible for generation and propagation
of the action potentials in the neurons and for conducting electrical signals throughout the
nervous system.
The distribution of the cardiac sodium channel Nav1.5 in the brain has not been
previously characterized at the protein level. Our study represents the first detailed
characterization of Nav1.5 protein distribution in the mouse brain. Consistent with the
distribution of Nav1.5 transcripts in rat and human brain (Donahue et al. 2000; Hartmann
et al. 1999), the mouse Nav1.5 protein was present in the olfactory system, thalamus, and
hypothalamus. However, our study revealed localization of Nav1.5 protein in several
brain regions that were not described or analyzed in previous studies. These regions
include the cerebral cortex, basal ganglia, and the white matter of the cerebellum.
Another difference between our study and the previous reports is related to the limbic
system. Hartmann et al. and Donahue et al. showed strong expression of Nav1.5 mRNA
in the piriform cortex, septal nuclei, the diagonal band of Broca, amygdala, and habenular
nuclei, whereas our study did not detect Nav1.5 protein in these structures. Instead, we
found weak or moderate presence of Nav1.5 protein in the nerve fibrous structures in
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these regions. A possible explanation for the difference between our study and the
previous studies may be that Nav1.5 mRNA is localized to the neuronal cell bodies,
whereas the Nav1.5 protein molecules are synthesized in these locations, and are
transported to and accumulate in the neuronal processes.
The implications of our study are two-fold: (1) Increasing evidence suggests that
the distinctive roles played by different brain Na channels are often dictated by their
unique localization in excitable tissues. Our finding that Nav1.5 protein is localized in the
neuronal processes in certain distinct regions of the brain, as well as the fact that
activation and inactivation of the Nav1.5 channels are voltage-dependent, may suggest
that Nav1.5 could aid in efficient nerve impulse generation and propagation in these
specific brain regions. Together with SCN12A, Nav1.5 channels generate the TTXresistant sodium currents in the brain, which may play a role in sustained firing of
neurons or as pace-makers; (2) We and others have established that mutations in Nav1.5
cause cardiac arrhythmias and sudden cardiac death associated with long QT syndrome
(LQTS), idiopathic ventricular fibrillation/Brugada syndrome, and cardiac conduction
disease (Chen et al. 1998; Wan et al. 2001; Wang et al. 1995b).
It has been recognized that the nervous system also plays a role in the genesis of
cardiac arrhythmias.

Fright, anger, depression, intense emotion, rigorous exercises,

swimming, alarm clocks, ringing telephones, and other activities related to the nervous
system can all trigger life-threatening arrhythmias. For LQTS, major genes have been
cloned or identified as the cardiac sodium channel gene Nav1.5 (LQT3) and potassium
channel subunit genes KCNQ1 (LQT1), and KCNH2 (LQT2) (reviewed in (Wang et al.
2001). Genotype-phenotype correlation studies (Schwartz et al. 2001) found that LQT2
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and LQT3 patients with mutations in Nav1.5 and KCNH2 (both of them are expressed in
the brain (Curran et al. 1995; Donahue et al. 2000; Emmi et al. 2000; Hartmann et al.
1999) frequently develop cardiac arrhythmias during sleep or at rest, whereas LQT1
patients with mutations in KCNQ1 (not expressed in the brain) (Wang et al. 1996)
experienced cardiac events during exercise. For idiopathic ventricular fibrillation with
ECG characteristics of right bundle branch block and ST segment elevation (also known
as Brugada syndrome), we established that Nav1.5 mutations that are functionally
different from LQT mutations are the underlying causes of this disease (Chen et al. 1998).
Interestingly, Brugada patients also develop life-threatening arrhythmias predominantly
during sleep (Matsuo et al. 1999).

Although it is speculative and remains to be

investigated, it is possible that mutant Nav1.5 proteins expressed in certain brain regions
of LQT3 patients may play a role in generating the trigger to provoke arrhythmias during
sleep or at rest. Of particular interest is the expression of Nav1.5 in the brainstem which
is known to be involved in regulating cardiac activities through autonomic motor neurons.
In conclusion, our results indicate that Nav1.5 protein is localized to the plasma
membrane of the neuronal processes within distinct regions of the brain. This study
provides new insight into a possible physiological role of Nav1.5 in brain function.
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CHAPTER V

GENERAL DISCUSSION AND FUTURE DIRECTIONS

My thesis focuses on functional regulation of the cardiac sodium channel Nav1.5.
First, I identified a novel regulatory protein, MOG1, as a key component of the cardiac
sodium channel Nav1.5 protein complex. I demonstrated that MOG1 exerted significant
effects on the function of the cardiac sodium channel (see Chapter II). The results
provide insights into the structure and function of the Nav1.5 protein complex in the
physiology of the cardiovascular system and reveal a novel functional role for MOG1.
Regulation of Nav1.5 in the pathological state was studied in a mouse model for long QT
syndrome, a lethal arrhythmia that causes sudden death, using genomic approaches. I
found that the LQT3 mutation N1325S in Nav1.5 was able to re-program the expression
of many genes. Of particular interest was the highly elevated expression of STAT1,
which may be related to cardiomyocyte apoptosis in transgenic N1325S hearts (see
Chapter III). To explore possible novel functional roles in the brain, the expression
profile of Nav1.5 protein was analyzed in the mouse brain. I showed that the Nav1.5
protein was localized to the plasma membrane of the neuronal processes within distinct
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regions of the brain (see Chapter IV). The results provide new insights into a possible
physiological role of Nav1.5 in the brain. Overall, my studies contribute to the field of
the functional characterization of Nav1.5, and my results have also expanded current
research of Nav1.5 to new directions that warrant future attention as described below.

5.1. MOG1 acts as an important regulator for the function of Nav1.5
MOG1 interacts with cardiac sodium channel Nav1.5, and the presence/absence of
MOG1 affects the sodium currents in both a heterologous transfection HEK293/Nav1.5
cell line and native neonatal cadiomyocytes. MOG1 was also shown to colocalize with
Nav1.5 at the intercalated discs of cardiomycytes. The results suggest that MOG1 may be
critical for modulating the function of cardiac sodium channel. There are several other
proteins that have been identified and reported in the Nav1.5 interacting protein complex
(Abriel et al. 2005, Allouis et al. 2006). These proteins include structural proteins
(ankyrin G, syntrophin/dystrophin), signaling proteins (FHF1B, calmodulin) and
enzymes (Nedd4, Fyn, PKA, PKC, SGKs, PTPH1). However, none of these proteins
have been shown to play a role in Nav1.5 function in a physiological context. The
functional study for these proteins were all performed in heterologous cell expression
systems, but not in native cardiac cells, and the effects on Nav1.5 were only evaluated by
overexpressing the potential interacting protein(s). We have analyzed the effects of
MOG1 on Nav1.5 in cardiomyocytes and examined the sodium current by knocking down
MOG1 expression in the mouse. It will be interesting to use siRNA technology to knock
down expression of the other Nav1.5-interacting proteins and compare their effects on
sodium currents to the effects we observed for MOG1.
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5.1.1. MOG1 may be involved in cell-cell communication
This thesis revealed the physiological function(s) of MOG1 in mammalian cells.
A previous study with Northern blot analysis demonstrated that the heart was the tissue
with the highest expression level of MOG1, suggesting that MOG1 plays an important
role in cardiac function (Marfitia et al.2001). The results from the present study further
define the role of MOG1 in the heart. We provide evidence that MOG1 the expression of
MOG1 was highly expressed in the intercalated discs of both atrial and ventricular cells
(Fig 2.8C), and colocalized with Nav1.5 at the intercalated discs of cardiomyocytes (Fig
2.8E). Moreover, the expression pattern of MOG1 was similar to the pattern shown by
connexin 43 (Fig 2.8C-D), the principal connexin of the working myocardium that
constructs the gap junction at intercalated discs of cardiac tissue. In addition, our results
are consistent with those of Malhotra research group whose work demonstrated that
Nav1.5 colocalizes with connexin-43 (Malhotra et al. 2004). Taken together, MOG1 and
Nav1.5 colocalize with connexin 43 at the intercalated disc of cardiomyocyte. The
expression of Nav1.5 at the intercalated disc implies that the action potential may jump in
saltatory fashion from one end of the cell to the other end via Nav1.5 channels (Sebastian
et al. 2001). It is speculated that co-localization of MOG1 and Nav1.5 at the intercalated
disc may play an important role in establishing and regulating electrical connections
between cardiomyocytes. Further analysis will be necessary to test this hypothesis. On
the other hand, our results shown MOG1 facilitates Nav1.5 expression on cell surface,
which suggests that MOG1 increases the conduction velocity of electrical impulse in
cardiac tissue.
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5.1.2. The possible molecular mechanisms for regulating the function of Nav1.5 by
MOG1
As demonstrated in Chapter IV, our results revealed an increase in Nav1.5
expression level in the plasma membrane and an increase in sodium currents when overexpressed with MOG1 (Fig 2.9). The detailed molecular mechanism by which MOG1
regulates the functional expression of Nav1.5 on plasma membrane remains to be further
defined. I showed that increased cell surface expression of Nav1.5 by MOG1 may be a
mechanism for increased sodium current densities by MOG1 and may potentially be
achieved through increased transport of Nav1.5 to cell surface and/or reduced
internalization/degradation of Nav1.5.
The trafficking of membrane proteins like Nav1.5 is a highly regulated process.
After being synthesized on ribosomes, the protein is incorporated into the endoplasmic
reticulum (ER), then transported from ER to the Golgi apparatus, and subsequently
trafficked to the cytoplasmic membrane. A critical step in this process is the transition
from the ER to Golgi compartment, which is reported to be related to the ER retention
motifs and ER export signals (Zhou et al. 2002). Little is known about regulation of
sodium channel transport from cis face to trans face of the Golgi complex, and from the
Golgi to the plasma membrane. There is a potential ER export signal (DXE) in the Cterminus of Nav1.5 that may regulate the exit of fully folded and assembled Nav1.5 out of
the ER (Herfst et al. 2004). Recently, ER retention signal (RXR), which retains newly
formed proteins in the ER, has been shown to play an important role in the trafficking of
many membrane proteins to the cell surface including calcium channel alpha1 subunit,
ATP-sensitive K+ channel, GABAB receptor and NMDA receptor (Bichet et al. 2000,
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Zerangue et al. 1999, Margeta-Mitrovic M, Scott et al. 2001). Lily Jan and colleagues
first demonstrated the function of ER retention motif RXR in ATP-sensitive K+ channel
trafficking to plasma membrane, and later Bichet et al. found that this retention motif also
mediated trafficking of Ca2+ channel α1 subunit to cell surface and proposed that binding
of β subunit is a mechanism for facilitating movement of channels to plasma membrane
by masking the ER retention signal in the α1 subunit (Bichet et al. 2000, Zerangue et al.
1999).
Inspection of the sequence of Nav1.5 revealed a total of six ER retention motifs
(RXR). Three ER retention signals are located in loop I between DI and DII which are
involved in mediating the trafficking of sodium channels by PKA (Zhou et al. 2002), one
at the C-terminus (at 2010-2012) next to the PDZ domain which is the interacting site for
syntrophin and PTPH1, and two at the cytoplasmic loop II between DII and DIII (at 986988 and 1193-1195) with unknown functions. Whether the two ER retention motifs in
Nav1.5 loop II play a similar role as those in KATP and calcium channels is an interesting
question. A working model is illustrated in Fig. 5.1. It should be interesting to test
whether these two ER retention motifs (RHR for 986-988 and RLR for 1193-1195) play
any role in the regulation of Nav1.5 trafficking to cell surface by MOG1. The two ER
retention motifs can be mutated and their effects on trafficking of Nav1.5 to cell
membrane can be analyzed by expressing wild type and mutant channels in mammalian
cell lines and comparing their differences on the expression levels on cell membrane.
The effects of MOG1 on ER retention can be tested by introducing a chimeric protein
CD8-loop II-Myc, in which the entire cytoplasmic sequence of CD8 is replaced by the
loop II-Myc sequence. This chimeric protein is then expressed in mammalian cell lines
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Fig. 5.1. A model for the MOG1-mediated increase in cell surface expression of
sodium channel Nav1.5. We have demonstrated that MOG1 is involved in the
trafficking of Nav1.5 to cell membrane. In the absence of MOG1, Nav1.5 is trapped
within the ER by binding onto an ER retention protein (ERRP) through the ER retention
motif(s) in the loop II. In the presence of MOG1, binding of MOG1 to Nav1.5 loop II
releases the retention brake and facilitates the transport of Nav1.5 to the plasma
membrane. The amino acids sequence of Nav1.5 loop II is shown upper left corner with
the two ER retention motifs highlighted. This model was adapted from Bichet D et al.
2000. Neuron 25:177–190.
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in the presence or absence of MOG1. The intracellular distribution of CD8-loop II-Myc
can be visualized by immunostaining. In the presence of MOG1, CD8-loop II-Myc is
expected to be mainly localized on cell membrane. These results will indicate that
MOG1 is required for ER exit of Nav1.5. To determine whether the increased cell
surface expression of Nav1.5 was the result of overexpression of MOG1 (by the
mechanism of enhanced ER exit of Nav1.5), we can compare the intracellular localization
of Nav1.5 in the presence or absence of MOG1. ER marker calnexin and Golgi marker
GM130 can be used to visualize the position for ER and cis-Golgi separately, as
described previously (Liu et al. 2007). Nav1.5 signals are expected to be increased in
Golgi and reduced in ER in the presence of MOG1 if MOG1 promotes trafficking of
Nav1.5 from the ER to Golgi complex.

5.1.3. Future Directions
Determination of the binding domains for the Nav1.5-MOG interaction Eight
mutations associated with Brugada syndrome, long-QT syndrome and sudden infant
death have been identified in the cytoplasmic loop II of Nav1.5 (Appendix A). The
mutation E1053K in Nav1.5 causing Brugada syndrome was shown to interrupt the
localization of Nav1.5 to cell surface mediated by ankyrin G (Mohler et al. 2004). In this
study we showed that MOG1 is another Nav1.5 cytoplasmic loop II interacting protein.
However, the specific binding sites in MOG1 and loop II of Nav1.5 remain to be
identified.

In the future, serial deletion analysis and site-directed mutagenesis in

combination with protein binding assays can be employed to identify the binding site(s).
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When a binding site is identified, it will reveal whether any disease-associated mutations
are located within the site and affect the binding of MOG1 to Nav1.5.
MOG1 may have effects on other sodium channels The sequence of Nav1.5 loop
II is highly homologous to two sodium channel isoforms, Nav1.8 and Nav1.9 which are
predominantly expressed in dorsal root and trigeminal ganglia (DRG). It is reasonable to
speculate that MOG1 may associate with these two sodium channels and has similar
biological effects on them as it does on Nav1.5. Similar experiments for studying Nav1.5
and MOG1 can be performed to test this hypothesis. In addition, as shown in Chapter IV,
Nav1.5 was demonstrated to be distributed widely through the central nervous system and
mainly localized to the axons at the cellular level. These results suggested that MOG1
may associate with Nav1.5 in the brain and have effects on regulating neuronal
excitability mediated by Nav1.5. MOG1 can be co-expressed with expression constructs
for Nav1.8 and Nav1.9 or other sodium channels in HEK-293 cells, and the effect of
MOG1 can be determined by measuring the sodium currents. These studies should be
able to determine whether the effect of MOG1 is specific for Nav1.5.
Identification of MOG1 mutations in arrhythmia patients Nav1.5 mutations
have been associated with Brugada syndrome and other types of lethal arrhythmias. The
fact that Nav1.5 mutations affect the cell surface expression (trafficking) suggests that
MOG1 may also be central and/or a contributor to many disease processes in the heart.
Genetic mutations in MOG1 may affect the expression and function of Nav1.5, leading to
similar cardiac diseases. Future mutational analysis of MOG1 in patients with various
arrhythmic disorders can be performed to test this hypothesis.

On the other hand,

identification of proteins like MOG1 that regulate expression and function of Nav1.5 may
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serve as interesting targets for developing interventional options to manage lethal
arrhythmias associated with Nav1.5 mutations or abnormalities. Furthermore, the present
findings provide new insights into the physiological role of MOG1 in vivo in mammalian
cells, and future studies of MOG1 will likely offer more insights on its role and its
relevance in myocardial function.

5.2. The increased expression of STAT1 in SCN5A N1325S transgenic mouse may
be involved in cardiomyocyte apoptosis
Abnormal calcium handling has been demonstrated in SCN5A N1325S transgenic
mice (Yong et al. 2007). Calcium ion antagonist verapamil was shown to reduce the
incidence of inhomogeneous AP in SCN5A N1325S transgenic mice (Yong et al. 2007).
This finding suggests that SCN5A N1325S mutation causes the remodeling of
intracellular calcium ion homeostasis in response to the [Na+]i overload. It was reported
that increased intracellular Ca2+ concentrations enhanced the phosphorylation of STAT1
and thus increased transcription activation of STAT1-dependent genes (Xu et al. 2005,
Nair et al. 2002). Indeed, several STAT1 mediated genes were also expressed abundantly
as a result of SCN5A N1325S mutation (see chapter III).

There is not yet direct

experimental evidence for the relationship between the expression level of STAT1 and
intracellular calcium influx. In the future, TG-NS mice can be treated with calcium
channel blockers (TG-WT as control), and [Ca2+]i and expression of STAT1 can be
measured. Decreased [Ca2+]i by calcium channel blockers may correlate with reduced
expression of STAT1, which will support the hypothesis that increased STAT1
expression in TG-NS mice may be related to abnormal calcium handling in these mice.
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In our study, STAT1 has been shown to be highly expressed in SCN5A N1325S
transgenic mice (Chapter III).

STAT1 has been shown as a preapoptotic factor.

Apoptosis was observed in our SCN5A N1325S transgenic mice (Zhang et al. 2007).
Therefore, STAT1 may mediate apoptosis in SCN5A N1325S transgenic mice. To test
this hypothesis, TG-NS mice can be breed to STAT1 knockout mice to determine
whether the absence of STAT1 can prevent apoptosis induced by SCN5A mutation
N1325S in TG-NS mice.

5.3. Nav1.5 is a candidate gene for brain disease
Chapter IV showed that the Nav1.5 protein was widely expressed in the central
nervous system, including the cerebral cortex, striatum, cerebellum, and brain stem.
Nav1.5 was also detected on the plasma membrane of the neuronal processes within
distinct regions of the brain. The implication of this finding is that Nav1.5 may play a
role in the physiology of the central nervous system. Interestingly, administration of
propranolol, which has a potential to block sodium channels, can correct the disorder of
habituation in schizophrenic patients. Recent work from Roberts et al. found that “an
aboriginal genetic defect in voltage-gated Na+-channel SCN5A can give rise to
susceptibility to schizophrenia” (Roberts et al. 2006). It has been known that another
type of sodium channel blocker, local anesthetics, can act as an anticonvulsant by
producing a conduction block in nerves and prevent a variety of seizures. On the other
hand, anticonvulsants such as phenytoin have a therapeutic effect for cardiac arrhythmias
by blocking sodium currents (Rogawski et al. 1990).

Abnormal neuronal activity

associated with Nav1.5 mutations might affect both the coordination of brain function and
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cardiac rhythm, which may trigger seizures, syncope, life-threatening arrhythmias, or
sudden death in arrhythmic and epileptic patients.

Screening Nav1.5 mutations in

schizophrenia and epilepsy patients may provide additional evidence to support this
hypothesis.
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Appendex A.

Summary of mutations associated with the Nav1.5 gene

Mutation 1

Coding effect

Region2

Disease3

G9V

Missense

N-terminal

LQT3

Millat G et al, 2006

R27H

Missense

N-terminal

BS

Priori S et al. 2002

G35S

Missense

N-terminal

BS

Nissenbaum E et al. 2001

Q55X

Nonsense

N-terminal

BS

Makita N et al. 2007

V95I

Missense

N-terminal

BS

Liang P et. Al. 2006.

R104Q

Missense

N-terminal

BS

Nissenbaum E et al. 2001

Splicing

N-terminal

BS

Sangwatanaroj S et al.

insertion

Reference

2002

K126E

Missence

DIS1

BS

Vatta M et al. 2002

E161K

Missense

DIS2

BS/SSS/

Smits J et al. 2002; Smits

PCCD

JP, 2005

BS/SSS

Makiyama T 2006

BS

Vatta M et al. 2002

DIS3-S4

AS

Makita N,2005

T187I,

Missense

DIS2-S3

20-bp

Frame-shift and DIS2–S3

Deletion

truncation

L212P

Missense
(Cx40)

S216L

Missense

DIS4

SIDS

Wang DW et al. 2007

T220I,

Missense

DIS4

DCM/SS

Olson TM, 2005, Benson

S

DW 2003

LQT3

Millat G, 2006

R225Q

Missense

DIS4

142

A226V

Missense

DIS4

BS

Priori Set al. 2002

I230V

Missense

DIS4

BS

Priori Set al. 2002

R282H

Missense

DIS5–S6

BS

Priori Set al. 2002

G292S

Missense

DIS5 -S6

BS

Niimura H et al.2004

V294M

Missense

DIS5–S6

BS

Priori S et al. 2002

NA

Nonsense

DIS5–S6

BS

Smits J et al. 2002

R282H

Missense

DIS5-S6

BS

Poelzing S et al.2006

K317N

Missense

DIS5-S6

BS

Yi SD, et al.2003

G319S

Missence

DIS5–S6

BS

Priori S et al. 2002

P336L

Missense

DIS5-S6

BS

Cordeiro et al. 2006

G351V

Missence

DIS5–S6

BS

Vatta M et al. 2002

T353I

Missense

DI S5-S6

BS

Pfahnl AE et al. 2007

R367H

Missense

DIS5–S6

BS

Vatta M et al. 2002

R367C

Missense

DIS5–S6

BS

Smits J et al. 2002

R367H

Missense

D1S5-S6

BS/AS

Takehara N, 2004

M369K

Missense

DIS5–S6

BS

Smits J et al. 2002

R376H

Missense

DIS5-S6

BS/PCCD Rossenbacker T, 2004

D356N

Missense

DIS5-S6

BS

Makiyama T 2006

393delF

Deletion

DIS6

BS

Priori S et al. 2002

N406S

Missense

DIS6

BS

Itoh H et al. 2005

E473X

Nonsense

DI-DII

BS

Baroudi G, 2004

K493

Deletion

DI–DII

BS

Smits J et al. 2002

G514C

Missense

DI–DII

PCCD

Tan H et al. 2001

143

R535X

Nonsense

DI–DII

BS

Smits J et al. 2002

BS/SIDS

Wan X et al. 2001

A572D

Missense

DI-DII

LQT3

A572D

Missense

DI-DII

LQT3

Paulussen A, 2003

delAL586-

in-frame deletion

DI-DII

SIDS

Wang DW et al. 2007

G615E

Missense

DI–DII

LQT3S

Yang P et al. 2002

L618F

Missense

DI–DII

LQT3S

Yang P et al. 2002

L619F

Missense

DI-DII

LQT3

Wehrens XH, 2003

G639R

Missense

DI-DII

LQT3

Millat G, 2006

R680H

Missense

DI-DII

SIDS

Wang DW et al. 2007

H681P

Missense

DI–DII

BS

Priori S et al. 2002

A735V

Missense

DIIS1

BS

Vatta M

A735E

Missense

DIIS1

BS

Priori S et al. 2002

G752R

Missense

BS

Smits J et al. 2002

587

Splice mutation

DIIS2

BS

Priori S et al. 2002

insertion

DIIS3-S4

DCM

Olson TM, 2005

W822X

Nonsense

DIIS4

BS

Keller DI, 2005

S835L

Missense

DIIS4 –S5

BS

F851L

Missense

DIIS5

BS

Priori S et al. 2002

F861fs951X

Nonsense

DIIS5

BS

Schulze-Bahr E, 2003

E867X

Nonsense

DIIS5-S6

BS

Schulze-Bahr E, 2003

2550-2551
insTG

144

L867X

Missense

DIIS5-S6

BS

Smits J et al. 2002

S871fs+9X

Frame-shift

DIIS5–S6

BS

Priori S et al. 2002

F891I

Missense

DIIS5–S6

BS

Priori S et al. 2002

C896S

Missense

DIIS5–S6

BS

Priori S et al. 2002

S910L

Missense

DIIS5–S6

BS

Priori S et al. 2002

NA

Frame-shift

DII-DIII

BS

Hofman-Bang J, 2006

S941N

Missense

DII–DIII

LQT3/SI

Schwartz Pet al. 2000

DS
R965C

Missense

DII–DIII

LQT3/BS

Sangwatanaroj

et

al.

2002, Priori S et al. 2002
A997S

Missence

DII–DIII

SIDS

Ackerman M et al. 2001

E1053K

Missence

DII–DIII

BS

Priori S et al. 2002

D1114N

Missense

DII–DIII

LQT3/BS

Sangwatanaroj S et al.
2002, Splawski I

et al.

2002
W1191X

Missense

DII-DIII

BS

Shin DJ et al. 2007

R1192Q

Missense

DII-DIII

BS

Vatta M et al. 2002

E1225K

Missense

DIIIS1

BS

Smits J et al. 2002

E1225K

Missense

DIIIS1-S2

BS

Schulze-Bahr E, 2003

R1232W

Missence

DIIIS1–S2

IVF/BS

Chen Q et al. 1998

R1232W

Missense

DIIIS1–S2

IVF/BS

Chen Q et al. 1998,

R1232W+

Missense

DIIIS1–S2

IVF/BS

Baroudi G et al. 2002

T1620M

145

K1236N

Missense

DIIIS1–S2

BS

Priori S et al. 2002

E1240Q

Missense

DIII–S2

BS

Priori S et al. 2002

F1250L

Missense

DIII–S2

LQT3

Yang P et al. 2002

NA

Frame-shift

BS

Smits J et al. 2002

G1262S

Missense

DIII-S2

BS

Shin DJ, 2004

D1275N

Missense

DIIIS3

DCM/AF

Olson TM, 2005,
Groenewegen WA, 2003

D1275N

Missense

DIIIS3

PCCD/AF Laitinen-Forsblom PJ,
2006

F1293S

Missense

DIIIS3–S4

BS

Priori S et al. 2002

E1295K

Missense

DIIIS4

LQT3

Abriel H et al. 2001

P1298L

Missense

DIIIS4

SSS

Benson DW, 2003

T1304M

Missense

DIIIS4

LQT3/SI

Wattanasirichaigoon Det

DS

al. 1999
Wang DW, 2007

IVS22DS+2

Splice mutation

DIIIS4–S5

PCCD

Schott J et al. 1999

G1319V

Missense

DIIIS4-S5

BS

Smits J et al. 2002

N1325S

Missense

DIIIS4–S5

LQT3

Wang Q et al. 1995

A1330P

Missense

DIIIS4–S5

LQT3/SI

Wedekind H et al. 2001

DS
A1330T

Missense

DIIIS4-S5

LQT3

Smits JP et al., 2005

S1333Y

Missense

DIII/S4-S5

SIDS

Millat G et al., 2006

F1344S

Missense

DIIIS5

BS/VF

Keller DI et al., 2006

146

S1382I

Missense

DIIIS5-S6

BS

V1398X

Nonsense

DIIIS5–S6

BS

Smits J et al. 2002
Chen

et

al.

1998,

Sangwatanaroj S et al.
2002
V1405L

Missense

DIIIS5–S6

BS

Smits J et al. 2002

G1406R

Missense

DIIIS5–S6

BS/PCCD

Smits J et al. 2002, Kyndt

/SSS

F et al. 2001
Benson DW et al. 2003

W1421X

Missense

DIIIS5-S6

LQT3

Niu DM et al.2006

R1432G

Missence

DIIIS5–S6

BS

Deschenes I et al. 2000,
Baroudi G et al. 2001

G1467fs+13

Frame-shift

DIIIS6

BS

Priori S et al. 2002

Splice mutation

c.4810+3_4

BS/PCCD Rossenbacker T et al.2005

X

810+6dupG
GGT
delK1479

Missense

DIII-DIV

BS

Schulze-Bahr E et al. 2003

F1486L

Missense

DIII-DIV

SIDS

Wang DW et al. 2007

delK1500

Deletion

DIII–DIV

LQT3/BS

Priori S et al. 2002

L1501V

Missense

DIII–DIV

LQT3

Splawski I et al. 2000

G1502S

Missense

DIII–DIV

BS

Smits J et al. 2002

1503

Deletion

LQT3

Wang Q et al. 1995

delKPQ

Deletion

LQT3

Wang Q et al. 1995

DIII–DIV

147

1505-1507
R1512W

Missense

DIII–DIV

BS

Rook M et al. 1999, Smits
J et al. 2002

Deletion

DIII-DIV

LQT3

Keller DI et al. 2003

IVS2AS-24

Splice mutation

DIVS

BS

Rook M et al. 1999

IVS21+1

Splice mutation

BS

Smits J et al. 2002

IVS24DS+28

Splice mutation

DIVS

BS

Rook M et al. 1999

K1527R

Missense

DIVS1

BS

Yokoi H et al. 2005

A1569P

Missense

DIVS2

BS

K1578fs/52

Missense

DIVS2

BS/SSS

Makiyama T et al. 2006

26AS-

Splice

BS

Hong K et al. 2005

5insTGGG?

(In-frame

delQKP
1507-1509

mutation DIVS2-S3

deletion)
D1595N

Missense

DIVS3

PCCD

Wang D et al. 2002

S1609W

Missense

DIVS3

LQT3

Millat G, 2006

D1595H

Missense

DIVS3

DCM

Olson TM, 2005

delF1616

Deletion

DIVS3-S4

LQT3

Splawski I et al.2000

delF1617

Deletion

DIVS3-S4

LQT3/BS

Splawski I et al.2000/Liang

/SSS

P et. al. 2006,
Benson DW et al. 2003

T1620M

Missense

DIVS3–S4

IVF/BS

Chen Q et al. 1998,

R1623X

Nonsense

DIVS4

SSS

Benson DW et al. 2003

148

R1623Q

Missense

DIVS4

LQT3

Splawski I et al. 2000

R1623L

Missense

DIVS4

LQT3

Splawski I et al. 2000

R1644H

Missense

DIVS4

LQT3

Splawski I et al. 2000

R1623X

Nonsense

DIVS4

BS/SSS

Makiyama T et al. 2006

R1623X

Nonsense

DIV-S4

BS

Todd SJ et al. 2005

R1632H

Missense

DIVS4

SSS

Benson DW et al. 2003

T1645M

Missense

DIVS4

LQT3

Wattanasirichaigoon D
etla. 1999

A1649V

Missense

DIVS4-S5

BS

Liang P et. al. 2006.

I1660V

Missense

DIVS5

BS

Cordeiro JM et al. 2006

S1710L

Missense

DIVS5–S6

IVF

Shirai N et al. 2002

delS1710

Deletion

PCCD

Schott J et al. 1999

D1714G

Missense

DIVS5-S6

BS

Amin AS et al.2005

delG5130

Frame-shift

DIVS5–S6

PCCD

Schott J et al. 1999

delG5280

Frame-shift

DIVS5–S6

BS

Schott J et al. 1999

G1740R

Missense

DIVS5-S6

BS

Baroudi G et al. 2004

G1740R

Missense

DIVS5–S6

BS

Priori S et al. 2002

G1743R

Missense

DIVS5-S6

BS

Valdivia CR et al. 2004

G1743E

Missense

DIVS5-S6

BS

Smits J et al. 2002

V1763M

Missense

DIVS6

LQT3

Chang CC et al. 2004

M1766L

Missense

DIVS6

LQT3/AV Valdivia C et al. 2002
block

I1768V

Missense

LQT3

149

Rivolta I et al. 2002

N1774+12X?

Nonsense

C-terminal

BS

Baroudi G et al. 2004

V1777M

Missense

C-term

LQT3

Lupoglazoff J et al. 2001

E1784K

Missense

DIVS6

LQT3/BS

Deschenes I et al. 2000

S1787N

Missense

DIVS6

LQT3

Splawski I et al. 2000

D1790G

Missense

DIVS6

LQT3

An Ret al. 1998

1795insD

Insertion

DIVS6

LQT3/IV

Bezzina C et al. 1999

F
Y1795C

Missense

C-terminal

LQT3

Y1795H

Missense

C-terminal

BS

insD1796

Insertion

C-terminal

LQT3/BS

Bezzina C et al. 1999

S1812X

Nonsense

C-terminal

BS

Schulze-Bahr E et al. 2003

D1819N

Missense

C-terminal

LQT3

Millat G, 2006

L1825P

Missense

LQT3

Makita N et al. 2002

R1826H

Missense

SIDS/LQ

Ackerman M et al. 2001

C-terminal

Rivolta I et al. 2001
Rivolta I et al. 2001

T3
D1840G

Missense

L1921stop

Nonsense

A1924T

Missense

C-terminal

C-terminal

LQT3

Benhorin J et al.1998

BS

Cormier J et al. 2002

BS/IVF

Smits J et al. 2002, Rook
M et al. 1999

V1951L

Missense

C-terminal

BS/SIDS

Priori S et al. 2002,Wang
DW, 2007

F2004L,

Missense

C-terminal

SIDS

Wang DW et al. 2007

P2006A

Missense

C-terminal

SIDS

Wang DW et al. 2007
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1

Standard single letter code is used for amino acids. X stands for nonsense mutation.
Examples for the mutations are as the following. G9V stands for a mutant in which
glycine is replaced by a valine at position 9. IVS22DS+2 stands for a mutant that insert
in +2 donor splicing site of intron 22. delAL586-587 stands for a mutant where Alanine
586 and Leucine 587 are deleted. 2Abbreviations for diseases are listed in List of
Abbreviations.
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Appendix B. Positive clones obtained from a yeast two hybrid screen. Different
DNA fragment of Nav1.5 as bait (upper panel) were used to screen a cardiac human
cDNA library, Further protein identification using the cytoplasmic loop II of Nav1.5 as a
bait was shown in the bottom panel.
Baits1

Number of positive clones

N-terminus

0

DI-II Linker (Loop I)

0

DII-III Linker (Loop II)

223

DIII-IV Linker (Loop III)

29

C-terminus

Self activating

1

The above table showed the results for yeast positive clones using baits from 5
cytoplasmic domain of Nav1.5: N-terminus, loops I, II, III and C-terminus.

Hits number2
Name of the protein
Gen bank number
2
Cardiac Troponin I
M64247
7
MOG1A
AF265206
2
The number of hits represents the number of positive yeast clones for the identified
protein.
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Appendix C. Additional genes showing differential expression in TG-NS hearts by
microarray analysis1

(A) Genes involved in immune response
Accession #

Symbo

Gene

P value

l
NM_010395

Fold

of

change

H2-T10 Histocompatibility 2, T region locus

2.6 x 10-5

13.3

10
BC027328

Brd4

Bone marrow stromal cell antigen 2

4.5 x 10-5

12.0

M16120

Tcrb-

T-cell

1.5 x 10-4

9.3

V13

reactive beta chain VNDNJC

Cd3z

CD3 theta T-cell receptor subunit

2.2 x 10-4

-7.2

L03353

receptor

insulin

B-chain

(B) Genes encoding enzymes
Accession #

Symbo

Gene

P value

l

Fold
change

NM_016966

Phgdh

3-Phosphoglycerate dehydrogenase

6.0 x 10-5

53.8

NM_008638

Mthfd2

Methylenetetrahydrofolate

3.6 x 10-4

13.3

5.610-4

-6.5

7.1 x 10-4

9.1

dehydrogenase (NAD+ dependent),
methenyltetrahydrofolate
cyclohydrolase
BC027199

Lrrk1

Leucine-rich repeat kinase 1

NM_080446

Helb

Helicase (DNA) B
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of

(C) Putative genes or genes with unknown functions
Accession #

Symbo

Gene

P value

l
BC020489

Fold
change

RIKEN cDNA 9130022K13 gene

2.4 x 10-4

231.3

Vig1-

cDNA clone F520004L04 gene,

7.6 x 10-4

25.6

pendin

similar

g

septicemia virus(VHSV) induced

consortium

6.6 x 10-4

17.2

RIKEN cDNA clone 2410118F17

4.1 x 10-4

13.4

2.1 x 10-4

25.4

5.8 x 10-4

11.2

7.4 x 10-4

10.1

9.6 x 10-4

9.8

231001
6F22Ri
k

BB741897

to

viral

hemorrhagic

gene 1
AF099975

Slfn4

Clone

I.M.A.G.E.

638739 schlafen4
AV212753

Asns

gene,

similar

to

Asparagine

synthetase
NM_030150

D11Lg

DNA segment, Chromosome 11,

p2e

Lothar Hennighausen 2,expressed

BB132493
BB329808

cDNA clone 9830001A05 gene
AW261 cDNA clone B630019O10
460

BQ033138

of

Oasl 2

cDNA clone UI-1-CF0-axe-c-08-0UI 3-, mRNA sequence, similar to
2-5 oligoadenylate synthetase-like 2
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BC023105

BB020681

BC023

Clone:MGC:28198

105

IMAGE:3989161

Srr

cDNA clone UI-1-CF0-axe-c-08-0-

6.7 x 10-4

7.7

4.4 x 10-4

5.3

2.1x 10-4

5.2

UI 3-, mRNA sequence, similar to
serine racemase
BB251523

Pycs

cDNA clone A730046N23, similar
to

pyrroline-5-carboxylate

synthetase short isoform
1

Genes involved in interferon-signaling pathways, apoptosis and inflammation are listed
in Table 3.2.
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